Global hypo-methylation in a proportion of glioblastoma enriched for an astrocytic signature is associated with increased invasion and altered immune landscape

James Boot¹, Gabriel Rosser¹, Dailya Kancheva², Claire Vinel¹, Yau Mun Lim³, Nicola Pomella¹, Xinyu Zhang¹, Loredana Guglielmi¹, Denise Sheer¹, Michael Barnes⁴, Sebastian Brandner³, Sven Nelander⁵, Kiavash Movahedi², Silvia Marino¹*

¹Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University, London, United Kingdom; ²Laboratory for Molecular and Cellular Therapy, Vrije Universiteit Brussel, Brussels, Belgium; ³Division of Neuropathology, The National Hospital for Neurology and Neurosurgery, University College London Hospitals NHS Foundation Trust, and Department of Neurodegenerative Disease, Queen Square, Institute of Neurology, University College London, London, United Kingdom; ⁴Centre for Translational Bioinformatics, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; ⁵Department of Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden

Abstract We describe a subset of glioblastoma, the most prevalent malignant adult brain tumour, harbouring a bias towards hypomethylation at defined differentially methylated regions. This epigenetic signature correlates with an enrichment for an astrocytic gene signature, which together with the identification of enriched predicted binding sites of transcription factors known to cause demethylation and to be involved in astrocytic/glial lineage specification, point to a shared ontogeny between these glioblastomas and astroglial progenitors. At functional level, increased invasiveness, at least in part mediated by SRPX2, and macrophage infiltration characterise this subset of glioblastoma.

Editor’s evaluation Overall, this paper represents a large amount of highly detailed work that identifies a hypomethylated subtype of glioblastoma that provides exciting foundations for further translational investigations.

Introduction Glioblastoma IDH-wildtype (now renamed glioblastoma) is a highly aggressive brain tumour (Wen and Kesari, 2008), with an extremely poor prognosis of 15 months’ median survival from diagnosis (Alcantara Llaguno and Parada, 2016). Glioblastoma is also the most prevalent primary adult brain tumour with an annual occurrence of approximately five cases per 100,000 people (Wen and Kesari, 2008; Omuro and DeAngelis, 2013) and a mean diagnosis age of 64 (Bush et al., 2017).
Part of the difficulty in researching and treating glioblastoma is the heterogeneity of the tumour, both at inter- and intra-tumoural levels. Inter-tumoural heterogeneity reflects differences at the (epi) genetic level which is illustrated by the classification of glioblastomas into different subgroups, such as the transcriptional subtyping proposed by the Verhaak group (Wang et al., 2017a), and the DNA methylation-based subtyping proposed by Sturm, 2012. However, seminal studies by multiple groups have established that there is also considerable intra-tumoural heterogeneity in glioblastoma (Patel et al., 2014; Neftel et al., 2019; Couturier et al., 2020). Established transcriptional glioblastoma subgroups profiles (Proneural, Neural, Classical, and Mesenchymal) are variably expressed in single cells from the same tumours (Patel et al., 2014) and tumour cells are characterised by distinct gene expression signatures and cluster separately from one another (Neftel et al., 2019). Single cells have also been shown to score highly for multiple gene expression signatures creating hybrid states, which further increases the heterogeneity of the tumour cell populations (Neftel et al., 2019). Couturier et al., 2020, found that tumour cells fell into a spectrum of states, whereby cells at one end of the spectrum expressed neuronal genes, whilst cells at the other end of the spectrum expressed astrocytic genes. Subgrouping based on DNA methylation subtyping alone (Capper et al., 2018) show less heterogeneity (Sturm, 2012), although some degree of heterogeneity has been reported in a small number of cases (Wenger et al., 2019). The tumour microenvironment also contributes to glioblastoma heterogeneity and the crosstalk between malignant cells and for example the inflammosome is well characterised (Daubon et al., 2020) with macrophages known to drive the transition of cancer cells towards a mesenchymal-like state (Hara et al., 2021).

Whether glioblastoma heterogeneity and its underlying epigenetic makeup is determined by the cell of origin or is acquired during transformation is a matter of debate. The putative cell of origin is thought to be a stem/progenitor cell that acquires the first genetic and/or epigenetic alterations that promote the formation of the tumour (Alcantara Llaguno and Parada, 2016). The debate over the cell of origin in glioblastoma centres around neural stem cells (NSCs) and lineage committed progenitor cells, such as oligodendrocyte, astrocytic, and neuronal precursor cells. NSCs are logically the prime candidate for the cell of origin of glioblastoma, because of their self-renewal potential, differentiation plasticity, and similarity in their gene expression with glioblastoma stem cells (here called glioblastoma initiating cells [GICs]) (Fan et al., 2019). A seminal study by Zheng et al., 2008, in mice, showed that deletion of both Trp53 and Pten by Cre recombinase under the control of the GFAP promoter increased the proliferative rate and self-renewal capability of NSCs, whilst also inhibiting their ability to differentiate into specific neural lineages, leading to transformation into high-grade malignant gliomas. Importantly, glioblastoma driver mutations have been identified in NSCs of the human subventricular zone (SVZ) in tissue samples obtained from patients, providing for the first-time evidence that these cells can act as cells of origin of glioblastoma in human (Lee et al., 2018). Further mouse studies (Alcantara Llaguno et al., 2015) have shown that inducing null alleles of Nf1, Trp53, and Pten using Cre recombinase under the control of NSC-specific Nestin, but also oligodendrocyte progenitor cell (OPC)-specific NG2 or bipotential progenitor cell-specific Ascl1 led to high-grade glioma, whilst no tumours formed when the same null alleles were induced in mature neurons (Camk2a-Cre), immature neurons (Neurod1-Cre), and adult neuronal progenitors (Dtx1-Cre) (Alcantara Llaguno et al., 2019). These studies together with other mouse studies have also shown that OPC (Liu et al., 2011; Lu et al., 2016) and astrocyte precursors (Chow et al., 2011) can behave as cell of origin of glioblastoma raising the possibility that tumours may originate from glial progenitor cells at different developmental stages, hence contributing to their heterogeneity.

Here, we leveraged pairs of patient-derived GICs and patient-matched expanded potential stem cells (EPSCs)-derived neural stem (Vinel et al., 2021) and progenitor cells to investigate the DNA methylation landscape of GICs as compared to their putative cell of origin in a patient-specific manner to further characterise glioblastoma heterogeneity and its ontogeny.

**Results**

**A DNA hypo-methylation bias in a subset of GBM**

We have recently described the generation of a cohort of 10 pairs of GICs and syngeneic induced NSCs (iNSCs), where the latter has been validated as a suitable proxy for endogenous NSCs at both transcriptional and epigenetic level (Vinel et al., 2021). Here, we have leveraged this resource (Vinel et al., 2021).
Boot et al., 2021) to investigate the DNA methylome of GICs as compared to syngeneic iNSCs. DNA methylation was assessed using the Illumina Infinium Methylation EPIC array and data processed as described in the Materials and methods. Across the 10 intra-patient comparisons, we visualised the distribution of the median probe delta M values and the proportion of these probes that were either hypo- or hyper-methylated, as well as the number and proportion of hypo- and hyper- methylated regions (differentially methylated regions [DMRs]) (Figure 1A, left panel). GICs 19, 30, 31, and 17 stood out as they had over 60% hypo-methylated DMRs, and together had a statistically significant larger proportion of hypo-methylated probes and DMRs as compared to the other six GICs in the cohort. These four GICs were identified as ‘hypo-bias’ – herein referred to as bias-GICs (B-GICs) (Figure 1A, left panel and Figure 1B). This subgrouping did not reflect the known DNA methylation-based classification of Sturm, 2012; three of the four B-GICs belonged to the RTKI (Proneural) subgroup and one to the RTKII (Classical) subgroup. The GICs without this hypo-bias, herein referred to as non-B-GICs (nB-GICs) were spread across the RTKI, RTKII, and Mesenchymal subgroups. Noticeably, the proportion of hypo-methylated and hyper-methylated DMRs was exaggerated, when patient-specific probes and DMRs were considered (Figure 1A, right panel).

Principal component analysis (PCA) of the 5000 most variable DNA methylation probes across all GICs in our cohort showed that principal component 1 (PC1) largely separated GICs by hypo-methylation bias, with three out of four B-GICs (19, 30, and 31, highlighted) clustering together on the left of the plot and all remaining GICs to the right (Figure 1C). A heatmap dendrogram of the beta values of the top 100 probes driving PC1 showed that these probes had much lower beta values in B-GICs 19, 30, and 31 relative to all other GICs, reflecting the separate cluster observed in the PCA (Figure 1D). This observation suggested that the hypo-methylation bias was GIC-driven, and not caused by the iNSC comparator, a conclusion which was confirmed when we performed non-syngeneic comparisons between each GIC and each of the iNSCs in our cohort (Figure 1E). GIC17 was found to be an exception as the proportion of hypo-methylated DMRs was not as high as the other three GICs (19, 30, and 31), and indeed this GIC did not cluster with GICs 19, 30, and 31 in the PCA plot (Figure 1C). However, the average percentage of hypo-methylated DMRs for this GIC was still greater than 60% regardless of the comparator used. Interestingly, the average percentage of hypo-methylated DMRs for GIC26 was also greater than 60%, despite the cell line not meeting this threshold in the syngeneic comparison, possibly due to significant variability of the two biological replicates (Figure 1—figure supplement 1). The proportion of hypo-methylated DMRs for the remaining GICs varied from 20% to 70%, however the mean percentage of hypo-methylated DMRs was below threshold (60%).

To validate this observation in an independent GIC cohort, DNA methylation data from the publicly available HGCC resource (Xie et al., 2015) was used. The HGCC dataset contains 71 GIC samples and given that non-syngeneic comparisons do not prevent the identification of the hypo-methylation bias (Figure 1E), these GICs were compared with iNSCs from our cohort. HGCC GIC lines underwent differential methylation comparisons against four different iNSC lines in turn to determine whether the results were consistent across comparisons. The reported percentage of hypo-methylated DMRs was found to be consistent regardless of the iNSC comparator used (Figure 1G), in keeping with the results of the non-syngeneic comparisons performed in our own cohort (Figure 1E). Given that the percentage of hypo-methylated DMRs in each GIC was determined four times – once for each iNSC comparator, each GIC had to meet a more lenient threshold of 50% hypo-methylated DMRs in all five iNSC comparisons in order to be classified as a B-GIC. Using this threshold, 46.5% of HGCC GICs were found to have a hypo-methylation bias. This was comparable with the proportion in our smaller cohort where we found 5/11 (45.5%) had greater than <50% DMRs and 4/11 (36.4%) had <60% DMRs. Next, for each HGCC GIC, the mean percentage of hypo-methylated DMRs when compared against all iNSCs was determined, to assess the extent of hypo-methylation bias for that GIC. HGCC GICs were stratified into a spectrum of states of either having no hypo-methylation bias (<50% hypo-methylated DMRs), a very low bias (>50%), low bias (>60%), medium bias (>70%), high bias (>80%), or very high bias (>90%). PCA of the 5000 most variable methylation probes across the HGCC GICs showed that PC1 separated patients on the extent of their hypo-methylation bias with very high B-GICs clustering to the right, and those with no bias clustering to the left (Figure 1F). TCGA subgroup classification confirmed no enrichment for a specific subgroup (of the 33 GICs deemed to have a hypo-methylation bias, 15 were Mesenchymal, 4 Proneural, 6 Classical, and 8
Figure 1. A DNA hypo-methylation bias in a subset of GBM. (A) The distribution of median probe delta M values (first row), the proportion of hypo- (red) and hyper- (blue) probes (second row), total number of differentially methylated regions (DMRs) (third row), and the proportion of hypo- and hyper-DMRs (fourth row) for each glioblastoma initiating cell (GIC)-induced neural stem cell (iNSC) comparison (left panel) and using patient-specific probes and DMRs (right panel). Samples with a hypo-methylation bias highlighted in green. (B) Percentage of hypo-methylated DMRs in bias-GICs (N=4) and Figure 1 continued on next page
non-bias-GICs (N=6), statistical significance tested using Welch’s t-test. (C) Principal component analysis (PCA) of all patient-derived GIC samples from our cohort, based on the top 5000 most variable methylation probes, GICs 19, 30, and 31 highlighted by red circle. (D) Heatmap dendrogram of the beta value z-scores of the top 100 methylation probes driving the variation of PC1 across all GICs and replicates in our cohort. (E) Percentage of hypo-methylated DMRs from all possible comparisons of GICs and iNSCs in our cohort, the mean percentage hypo-methylated DMRs for each GIC is represented by a horizontal black line. (F) PCA of all patient-derived GIC samples from the HGCC cohort, based on the top 5000 most variable methylation probes. (G) Heatmap summary of the percentage of hypo-methylated DMRs from all possible comparisons of HGCC GICs and five iNSCs from our cohort. (H) Number (bottom panel) and proportion (top panel) of hypo- and hyper-DMRs for each patient comparison between formalin fixed paraffin embedded (FFPE) bulk tumour and iNSC, repeated in the right panel for patient-specific DMRs from the same comparisons.

The online version of this article includes the following source data and figure supplement(s) for figure 1:

Source data 1. Source data for Figure 1.

Figure supplement 1. Hypo-methylation bias does not globally impact on transcription, but bias-glioblastoma initiating cells (B-GICs) are transcriptionally different from non-B-GICs (nB-GICs).

**Figure supplement 1—source data 1.** Source data for Figure 1—figure supplement 1.

Neural), in keeping with the interpretation that the hypo-methylation bias observed is spread across the known glioblastoma subgroups.

Finally, formalin fixed paraffin embedded (FFPE) tumour tissue, which was available for all 10 GIC/iNSC pairs of our cohort, was used as the neoplastic comparator to exclude that the observed hypo-methylation bias was induced in GIC by in vitro culture. Once again, tumours 19, 30, 31, and 17 showed a greater proportion of hypo-methylated DMRs than the remaining six comparisons (Figure 1H, left panel), and the proportion of hypo-methylated DMRs increased when only considering patient-specific DMRs (Figure 1H, right panel).

In conclusion, we have identified a subset of glioblastoma that harbour a DNA hypo-methylation bias when either the bulk tumour or GIC derived thereof are compared to iPSC-derived NSC.

**B-GICs are transcriptionally distinct from nB-GICs**

We used matched transcriptomic data from our GICs to assess any impact on transcription of the hypo-methylation bias. PCA based on the top 20% most variably expressed genes recapitulated the grouping of GICs observed at DNA methylome level (Figure 1—figure supplement 1B) with PC1 largely distinguishing the B-GIC and nB-GIC groups. Three out of four of the B-GICs (17, 19, and 30) grouped together to the right of the PC1 along with one biological replicate from GIC26 – a line characterised by substantial variability between replicates (Figure 1—figure supplement 1A). This grouping of GICs 17, 19, 26, and 30 did not correspond to their transcriptional GBM subgroup as they are RTKII, RTKI, MES, and RTKI, respectively. The remaining nB-GICs largely clustered together to the left of the PC2, with one of the B-GICs – GIC31 – lying between these two groups. Despite these differences at transcriptome level, patient-matched pairs of GICs and iNSCs did not reveal a bias in the directionality of differentially expressed genes (DEGs) (Figure 1—figure supplement 1C), indicating that the hypo-methylation bias does not translate to a bias in gene up- or down-regulation. Known genes associated with epigenetic remodelling or DNA methylation such as DNMTs or TETs were not identified within the DEGs (Supplementary file 1).

Next, we queried whether the hypo-methylation bias impacted miRNA expression and carried out small RNAseq. Clustering of the 500 most variably expressed miRNAs did not recapitulate the grouping of samples into B-GICs and nB-GICs (Figure 1—figure supplement 1D). Similarly, comparisons between GICs and iNSCs did not reveal a bias in directionality of expression of differentially expressed miRNAs (Figure 1—figure supplement 1E). Interestingly though, we identified five miRNAs differentially expressed in the same direction in all B-GICs (Figure 1—figure supplement 1F). Some of these five differentially expressed miRNAs have previously been linked either directly or indirectly to neural development and/or glial lineage specification. Silencing of miR-1275 induces GFAP (an astrocyte marker) expression in glioblastoma cells (Mai et al., 2019), and its down-regulation was associated with oligodendrogliia differentiation of tumour cells (Katsushima et al., 2012) – similarly in our dataset this miRNA is down-regulated. The JAK/STAT pathway, which is known to be a key regulator of astrocyte differentiation and activation (Xiao et al., 2010; He et al., 2005; Bonni et al., 1997; Ceyzériat et al., 2016), is thought to be up-regulated by miR-4443, which is down-regulated in our GICs. Finally, miR-196, which is up-regulated in B-GICs, plays an essential role in neural development.
as it helps regulate Homeobox (HOX) genes (Sehm et al., 2009), some of which have been shown to play a role in astrocyte biology (Vivinetto et al., 2020).

In summary, the hypo-methylation bias identified here did not lead to a bias in up- or down-regulation of gene or miRNA expression at a global level. However, PCA of the most variable genes indicated that there were transcriptional and regulatory differences between B-GICs and nB-GICs. One such difference was the differential expression of miRNAs involved in glial lineage specification.

**Binding of transcription factors linked to DNA methylation and glial lineage specification are enriched at hypo-methylated loci in B-GICs**

We used Homer (Heinz et al., 2010) to identify transcription factor (TF) binding sites that are enriched at hypo-methylated DMRs from B-GICs (17, 19, 30, and 31). We hypothesised that hypo-methylated DMRs were enriched for specific TF binding motifs linked to DNA methylation and/or glial lineage specification given the identification of miRNAs associated with glial differentiation (Figure 1—figure supplement 1E). Firstly, the hypo-methylated DMRs from the B-GICs-iNSC comparison were compared against DMRs from all GIC-iNSC comparisons. The top five enriched motifs were matches for an array of zinc-finger proteins, HOX genes, and families of factors such as hepatocyte nuclear factor 4 (HNF4), Kruppel-like factors (KLF), nuclear factor I (NFI), and distal-less homeobox (DLX) (Figure 2A). We noticed that some of these TFs, namely NFI, ET4V, DLX, and KLF have been previously linked to astrocyte/glial differentiation (Sanosaka et al., 2017; Yin et al., 2015; Marshall and Goldman, 2002).

To address the link to DNA methylation more stringently, motif enrichment analysis was performed on hypo-methylated DMRs identified from the B-GIC when compared to their syngeneic iNSC, relative to the hypo-methylated DMRs from nB-GICs when compared to their syngeneic iNSC. We reasoned that the hypo-methylated DMRs present in nB-GICs are a background of hypo-methylated DMRs. Therefore, comparing against this background should identify TFs that have potentially contributed to the hypo-methylation of DMRs specifically in the B-GICs. The top five enriched motifs were found to be matches for some of the same TFs identified in the first analysis such as PLAGL1, NFI family members, and ETS variant transcription factor 4 (ETV4) (Figure 2B). Interestingly, the fifth ranked enriched motif from this analysis was a strong match for members of the SOX family, known to be involved in cellular differentiation and neural development (Kamachi and Kondoh, 2013).

Next, Homer was used to identify the most enriched motifs in hyper-methylated DMRs from the B-GIC-iNSC comparisons, compared to DMRs from all other GIC-iNSC comparisons. We reasoned that hyper-methylated DMRs from B-GICs should not be enriched for any factors that may have caused the hypo-methylation bias. Therefore, any motifs found to be enriched in this comparison would have had to be disregarded. Importantly, PLAGL1, NFI, or ET4V were not identified in this analysis (Figure 2C).

Therefore, we hypothesised that TFs such as the NFI family could be responsible for the hypomethylation bias, as they have been shown to demethylate specific loci (Sanosaka et al., 2017), including lineage defining genes.

To test this hypothesis, we leveraged the availability of patient-specific iNSCs to generate induced astrocyte progenitor cells (iAPCs). DNA methyleme and transcriptome were analysed in five different progenitor lines at a differentiation stage, where cells co-expressed the astrocytic lineage marker CD44 (Liu et al., 2004) and the neural progenitor marker RESTN (Bernal and Arranz, 2018), in keeping with a astrocytic progenitor state (Figure 2—figure supplement 1A, B). Acquisition of a pro-inflammatory response upon IL6 treatment (Figure 2—figure supplement 1C, D), confirmed the astrocytic commitment of the cells. PDGFRα induced OPCs (iOPCs) were also generated for comparative analysis (Figure 2—figure supplement 1E, F). Inspection of the DNA methylation and RNAseq datasets obtained from these cells confirmed that iAPCs and iOPCs were epigenetically and transcriptionally distinct from one another and from the cells from which they were derived (Figure 2D, E). Furthermore, both cell types were found to be enriched for an astrocytic and oligodendrocyte signature, respectively (Figure 2F, G, H).

Differential methylation analysis was then carried out in a syngeneic fashion, between each of the five iAPCs and their matched iNSC samples. Hypo-methylated DMRs in all iAPC lines were identified and motif enrichment analysis performed on these regions, comparing against the sequences of all other iAPC - iNSC DMRs. The top five ‘de novo’ enriched motifs were matches for binding sites...
Figure 2. Hypo-methylated differentially methylated regions (DMRs) from bias-glioblastoma initiating cells (B-GICs) are enriched for transcription factor binding sites linked to glial differentiation. (A) Top five motifs enriched in all hypo-methylated DMRs from B-GICs as compared to all other DMRs from all GICs. (B) Top five motifs enriched in all hypo-methylated DMRs from B-GICs as compared to all the hypo-methylated DMRs from all other GICs. Figure 2 continued on next page.
Cancer Biology

Figure 2 continued

(C) Top five motifs enriched in all hyper-methylated DMRs from B-GICs as compared to all other DMRs from all GICs. (D) 3D principal component analysis (PCA) of methylation data from patient-derived fibroblasts, induced pluripotent stem cells (iPSCs), induced neural stem cells (iNSCs), induced astrocyte progenitor cells (iAPCs), induced oligodendrocyte progenitor cells (iOPCs), and publicly available reference datasets of NSCs, astrocytes, and oligodendrocyte precursor cells. (E) Unsupervised hierarchical clustering based on the top 5000 variable methylation probes of iAPCs, iOPCs, iOPCs (purple bar), and publicly available reference datasets (yellow bar). (F) Single sample gene set enrichment analysis (ssGSEA) enrichment scores for the astrocyte composite signature (ACS) of iAPCs (N=10), iNSCs (N=10), and publicly available reference datasets, statistical differences tested with one-way ANOVA. ssGSEA enrichment scores of iOPCs (N=10) and iNSCs (N=10) for the Oligodendrocyte Specific-300 (G) and Oligodendrocyte Enriched-300 (H) gene signatures, statistical significance tested using Mann-Whitney t-test. Top five de novo (I) and known (J) motifs enriched in all hypo-methylated DMRs in iAPCs, from each iAPC versus iNSC comparison.

The online version of this article includes the following source data and figure supplement(s) for figure 2:

Source data 1. Source data for Figure 2.

Figure supplement 1. Characterisation of induced astrocyte progenitor cell (iAPC) and induced oligodendrocyte progenitor cell (iOPC) obtained from induced neural stem cell (iNSC).

Figure supplement 1—source data 1. Source data for Figure 2—figure supplement 1.

previously found to be enriched in the comparison of hypo-methylated DMRs from B-GICs (Figure 2A, B). In particular, the top enriched motif was a strong match for ETV4 confirming the link between this factor and hypo-methylated astrocyte associated loci (Figure 2I). The NFI binding motif was the fifth-ranked enriched motif among the ‘known matches’ from Homer (Figure 2J). ETV4 and NFI binding sites were not identified as enriched in either the ‘de novo’ or ‘known matches’ when motif enrichment analysis was performed on hypo-methylated DMRs from iOPCs-iNSC comparison against all other DMRs (Figure 2—figure supplement 1G, H). Instead, hypo-methylated DMRs in iOPCs as compared to iNSCs were enriched for the binding sites of ZIC genes, HOX genes, SOX genes, and an array of zinc-finger proteins (Figure 2—figure supplement 1G, H).

In conclusion, hypo-methylated DMRs from B-GICs are enriched for TF binding sites, including ETV4 and NFI, that have been linked to glial differentiation. iAPC hypo-methylated loci are similarly enriched for these TF binding sites, a phenomenon which is specific to the astrocytic lineage. These results raise the possibility that B-GICs have undergone glial priming prior to, or during, neoplastic transformation.

A positive correlation between DNA hypo-methylation and astrocyte signature enrichment

Next, we assessed whether B-GICs were enriched for specific signatures of the glial lineage. We performed single sample gene set enrichment analysis (ssGSEA) on our cohort of GICs for an early radial glia (early-RG) signature (Nowackowski et al., 2017), a bespoke astrocytic signature, termed astrocyte composite signature (ACS) and two oligodendrocyte signatures (termed OPC Enriched-300 and OPC Specific-300), see Materials and methods for further details on these signatures. All GICs scored highly for the early-RG signature with little variability between lines (Figure 3—figure supplement 1A), likely reflecting the high degree of transcriptional similarity between GICs and NSCs. Four out of four B-GICs (17, 19, 30, and 31) had significantly higher enrichment scores for the ACS than the two OPC signatures (Figure 3A). GICs 50 and 26 showed a significant difference between the enrichment scores for the ACS and OPC signatures, however with a greater degree of variability between the two biological replicates. All other GICs showed no significant differences in enrichment scores for the gene signatures (Figure 3A). We further scored matching bulk FFPE tumour tissues for the ACS and two OPC signatures and found that the pattern of enrichment was not retained in the bulk tumours with very few tumours scoring highly for the ACS and the majority of tumour scoring highly for the OPC signatures (Figure 3—figure supplement 1C).

To validate these results, ssGSEA was performed on the GICs of the HGCC cohort (Xie et al., 2015). A subset of GICs that are highly enriched for the ACS were also identified in this cohort (Figure 3—figure supplement 1B). As there were no replicates for these GIC lines, we determined thresholds for the enrichment scores that separated the samples into enriched and non-enriched.
Figure 3. A positive correlation between DNA hypo-methylation and astrocyte signature enrichment. (A) Single sample gene set enrichment analysis (ssGSEA) enrichment scores of glioblastoma initiating cells (GICs) (N=2) for three different gene signatures; ACS (red), OPC Enriched-300 Signature (blue) and OPC Specific-300 Signature (teal), statistical significance tested using two-way ANOVA. Green dashed line indicating threshold for enrichment. (B) ssGSEA enrichment scores based on pseudo-bulk (aggregated within a patient) data of the cancer cell subset from the single-cell RNA
sequencing (scRNAseq) glioblastoma tumour data from Pombo Antunes et al., 2021, and Neftel et al., 2019, for three different gene signatures, ACS (red), OPC Enriched-300 Signature (blue), and OPC Specific-300 Signature (teal). (C) Percentage of single cells for each tumour, which scored the highest for one of the three different signatures: ACS (red), OPC Enriched-300 Signature (blue), and OPC Specific-300 Signature (teal). Green dashed line indicating threshold for enrichment. (D) Scatter plot of the ACS enrichment score and the percentage of hypo-methylated DMRs for each of the GICs from our cohort, when comparing to iNSCs from our cohort. (E) Scatter plot of the ACS enrichment score and the percentage of hypo-methylated differentially methylated regions (DMRs) for each of the HGCC GICs, when comparing to induced neural stem cells (iNSCs) from our cohort. (F) Volcano plot of differentially expressed genes (DEGs) identified from the comparison of BE-GICs versus nBE-GICs (glm model used for differentially expressed [DE] analysis). (G) Volcano plot of DEGs identified from the comparison of BE-GICs versus nBE-GICs from the HGCC cohort (glm model used for DE analysis). (H) Summary of pathway analysis performed using gProfiler, using the DEGs identified in (F) and (G).

The online version of this article includes the following source data and figure supplement(s) for figure 3:

**Source data 1.** Source data for **Figure 3**.

**Figure supplement 1.** Characterisation of the positive correlation between DNA hypo-methylation and astrocyte signature enrichment.

**Figure supplement 1—source data 1.** Source data for **Figure 3—figure supplement 1**.

Firstly, enriched cell lines had to have a higher-than-average enrichment score for the ACS (>0.8429). Secondly, ACS enrichment scores had to be 10% greater than any of the OPC signature scores. Given these criteria, 55% of the samples were found to be enriched for the ACS in the HGCC dataset, compared to approximately 64% in our cohort, hence confirming an ACS enrichment in an independent GIC cohort.

Next, single-cell RNA sequencing (scRNAseq) data of glioblastomas from two different sources (Neftel et al., 2019; Pombo Antunes et al., 2021) were interrogated to validate the signature enrichment observed in a proportion of GICs. The analysis of the integrated scRNAseq dataset of 15 glioblastomas showed presence of cancer cells, immune cells, oligodendrocytes, and a small cluster of endothelial cells. To identify patients enriched for the ACS signature, we employed two strategies. Firstly, by treating all the single cancer cells’ expression as pseudo-bulk tumour tissue, we were able to identify a subset of tumours, which scored higher for the ACS than the two OPC signatures (MGH105, MGH114, MGH143, ND2, and ND4) (Figure 3B). Secondly, we determined enrichment scores for single cancer cells from each tumour and then assigned a signature identity to each cell to quantify the percentage of ACS, OPC Enriched-300, or OPC Specific-300 cells per tumour. Encouragingly the same tumours found to have a higher ACS enrichment score based on the pseudo-bulk analysis, had increased proportion of ACS cells: 75.07% ± 19.40% compared to 26.26% ± 11.69% in the remaining tumours (Figure 3C). Finally, we applied these same two approaches but using the six cancer gene signatures from Neftel et al., 2019 (astrocytic: ‘AC’; mesenchymal: ‘MES1’ and ‘MES2’; oligodendrocyte progenitor-specific: ‘OPC’; and neural progenitor-specific: ‘NPC1’ and ‘NPC2’). The same five patients (MGH105, MGH114, MGH143, ND2, and ND4) had higher enrichment scores and proportions of cancer cells, assigned to the astrocytic signature (‘AC’) compared to the OPC signature, and the same held true for MGH115, MGH118, MGH124, MGH125, ND1, and ND6. For patients MGH143, ND2, and ND4, as well as for MGH115, MGH118, and ND5, the ‘AC’ signature showed highest enrichment and percent assigned cells within the six studied gene modules (Figure 3—figure supplement 1D, E). Interestingly, we noted that the ACS from our study enveloped the ‘MES1’, ‘MES2’, and ‘AC’ signatures from Neftel et al., 2019 (Figure 3—figure supplement 1F, G) but scoring B-GICs from our cohort for the Neftel et al., 2019, signatures did not allow to further dissect the enrichment type as three out of four B-GICs (17, 19, and 30) scored most highly for the ‘MES1’ and ‘MES2’ signatures as well as the ‘AC’ signature, GIC31 scored very similar for all Neftel et al. signatures (Neftel et al., 2019; Figure 3—figure supplement 1H).

A significant positive correlation was found between GIC ACS signature enrichment scores and the percentage of hypo-methylated DMRs in both our (Figure 3D, L) and in the HGCC cohorts (Figure 3E, M), raising the possibility that the two findings could be causally related.

To further explore the link between hypo-methylation bias and ACS enrichment, a differential expression analysis comparing B-GICs enriched for the ACS (termed bias-enriched [BE-GICs]), and GICs not harbouring a hypo-methylation bias and not enriched for the ACS (termed non-bias-enriched [nBE-GICs]) was performed. The BE-GIC group contained GICs 17, 19, 30, and 31, whilst the nBE-GIC group contained GICs 18, 26, 50, 52, 54, and 61. We reasoned that DEGs from this comparison could highlight key biological differences between BE-GICs and nBE-GICs. Of the 465 DEGs...
et al., 2018). Analysis of the pattern of expression of up-regulated in the comparisons between iNSC and iAPC across all patients, and its expression was leukaemia inhibitory factor (LIF).

Figure 4D (summarised schematically in Figure 4—figure supplement 1A) showed increased invasiveness (Figure 4A, B, C), despite having a smaller tumour core (Figure 4—figure supplement 1B, C, D).

To identify genes that may contribute to the phenotypic characteristics of the BE-GICs, the following differential expression comparisons were performed on a patient-by-patient basis, for four patients whereby two biological replicates of iAPCs, iNSCs, and GIC were available: GIC versus iAPC, iAPC versus inNSC, and GIC versus inNSC. We aimed to identify genes that play a role in the differentiation of iAPCs that are also deregulated in GICs and may be responsible for astrocytic signature enrichment in BE-GICs. Initially, DEGs present in both the GIC versus iNSC, and iAPC versus iNSC comparisons were selected for further analysis, for three reasons. Firstly, these DEGs could play a role in the differentiation of iNSCs to iAPCs if they are differentially expressed between these two cell types. Secondly, as these DEGs are also differentially expressed between GICs and iNSCs, they may play a role in neoplastic transformation. Thirdly, as these DEGs are not differentially expressed between iAPCs and GICs, they could contribute to the enrichment for an astrocytic signature. Once DEGs meeting these criteria had been identified across our four patients, we further selected for genes also present in the ACS, and specifically identified in the comparison of BE-GIC 19 and 31 and shared between the two (summarised schematically in Figure 4—figure supplement 1A).

GLI pathogenesis related 1 (GLI1), sushy repeat containing protein X-linked 2 (SRPX2), and leukaemia inhibitory factor (LIF) were identified (Figure 4D). GLI1 is very well studied in cancer (Awasthi et al., 2013) and has been found to regulate migration and invasion of glioma cells (Ziv-Av et al., 2015; Giladi et al., 2015). Similarly, LIF is well studied in glioma and has been shown to contribute to the maintenance of glioma-initiating cell self-renewal (Edwards et al., 2017; Peñuelas et al., 2009). Moreover, LIF has been shown to help mediate astrocyte differentiation (Nakashima et al., 1999). The pathogenic role and impact of SRPX2 in GBM (Tang et al., 2016) is less well characterised, despite being well studied in cancer (Hong et al., 2018; Tanaka et al., 2009; Lin et al., 2017; Zhang et al., 2018). Analysis of the pattern of expression of SRPX2 in our dataset found that it was up-regulated in the comparisons between iNSC and iAPC across all patients, and its expression was...
Figure 4. Increased invasion in xenografts derived from BE-GICs and role of SRPX2 in regulating invasion in vitro. (A) and (B) Representative images of human vimentin-stained xenograft tumours with overlayed image analysis. Red outline is the detected tumour core, blue outline is the detected gross tumour edge. (C) Invasive index scores of xenografts from BE-GICs (N=4) and other GICs (N=8), statistical significance tested using un-paired t-test. (D) Overview of significant differentially expressed genes (DEGs) that are present in the astrocyte composite signature (ACS) and are identified.

Figure 4 continued on next page
in glioblastoma initiating cell (GIC) versus induced neural stem cell (iNSC) and induced astrocyte progenitor cell (iAPC) versus iNSC comparisons across patient comparisons. (E) Expression (transcripts per million [TPM]) of SRPX2 in the three cell types analysed: iAPC (orange), iNSC (red), and GIC (turquoise). (F) Expression of target genes in glioblastoma tissue (N=528) as compared to non-tumour tissue (N=10), data acquired from Gliovis (Bowman et al., 2017), statistical significance tested using Mann-Whitney t-test. (G) Expression of target genes in BE-GICs (N=13) versus nBE-GICs (N=4) from the HGCC cohort, statistical significance tested using Mann-Whitney t-test. (H) Kaplan-Meier curve for GBM patients with high expression (red) versus low expression (blue) of SRPX2, produced using TCGA data available on Gliovis (Bowman et al., 2017). (I) Relative fold change in mRNA expression of SRPX2 as determined by qPCR for GIC short hairpin RNA (shRNA) knockdown lines, statistical significance tested using t-test (N=3). (J) Representative western blot of SRPX2 in U3118 shRNA knockdown lines. (K) Relative fold change in SRPX2 protein expression as determined by western blot for GIC shRNA knockdown lines, statistical significance tested using t-test (N=3). (L) Inagination assay results: average number of nuclei per image field of GIC SRPX2 knockdown lines, statistical significance tested using two-way ANOVA (N=3-4). (M) Z-score of SRPX2 expression in different tumour regions according to Ivy GAP (Puchalski et al., 2018) (N=19-111). (N) Correlation of ACS enrichment scores (y-axis) and enrichment scores for a signature of the top 200 up-regulated genes in regions of microvascular proliferation and hyperplastic blood vessels (x-axis) in single tumour cells from Pombo Antunes et al., 2021. (O) Neurosphere assay results: log fraction of the number of non-responding cultures at specified cell counts for U3118 SRPX2 knockdown lines. (P) Table of estimated stem cell frequencies and confidence intervals as determined by the neurosphere assay results and extreme limiting dilution assay analysis.

The online version of this article includes the following source data and figure supplement(s) for figure 4:

Source data 1. Source data for Figure 4.

Figure supplement 1. Characterisation of xenografts derived from BE-GICs and role of SRPX2 in regulating glioblastoma initiating cell (GIC) properties.

Figure supplement 1—source data 1. Source data for Figure 4—figure supplement 1.

specifically higher in the GICs of patients 19 and 31 (Figure 4E), as expected. Given our limited cohort size, the deregulation of SRPX2 was further validated in other datasets and found that it was more highly expressed in glioblastoma tumour tissue as compared to non-tumour brain tissue according to TCGA data (Figure 4F) and in BE-GICs from the HGCC cohort (Figure 4G). Using survival data from the TCGA we also found that high SRPX2 expression confers a worse prognosis (Figure 4H). To elucidate the role of SRPX2, the HGCC BE-GIC line, U3118, and GIC19 were transduced with lentiviral vectors, carrying short hairpin RNA (shRNA) constructs targeting SRPX2 (termed SRPX2_90 and SRPX2_91) and a scramble control. The mRNA levels of SRPX2 were decreased upon silencing (Figure 4I) and western blotting confirmed effective knockdown of the gene at the protein level (Figure 4J, K).

The differential expression comparison between BE-GICs and nBE-GICs identified cell movement/ invasion among the differentially enriched pathways and BE-GICs gave rise to more invasive tumours upon intracerebral injection in mice. Cell movement/invasion is a process that is also impacted in astrocytic progenitors, which are more motile as compared to NSC (Schiweck et al., 2018). For these reasons, the impact of SRPX2 knockdown on the invasive phenotype of GICs was assessed using a transwell invasion assay. The nuclei of cells that moved across the transwell membrane were fixed 24 hr after seeding, then stained and counted as described in the Materials and methods. On average, a statistically significant lower number of nuclei per image field were found in both GIC19 and U3118 SRPX2 knockdown lines (Figure 4L) (p-value < 0.0001).

Interestingly, interrogation of the Ivy GAP (Puchalski et al., 2018) resource revealed SRPX2 expression predominantly in perivascular regions, including areas of microvascular proliferation and hyperplastic blood vessels, whilst it was down-regulated in the parenchymal leading edge and infiltrating tumour (Figure 4M). Given that gliomas invade mainly along two routes, the white matter tracts and the blood vessels (Giese and Westphal, 1996), it could be speculated that SRPX2 may play a role in the latter and not the former in the subset of glioblastoma with hypomethylation bias/astrocytic signature enrichment. Although functional studies in vivo will be required to substantiate this hypothesis, we scored single tumour cells from the scRNAseq data of Pombo Antunes et al., 2021, for both the peri/microvascular signature (top 200 genes up-regulated in these regions according to Ivy GAP; Puchalski et al., 2018), the ACS and the two OPC signatures. This showed that the scores for the peri/microvascular signature and the ACS were positively correlated (Figure 4N), whilst the former and the OPC signatures were not (Figure 4—figure supplement 1F, G).

Proliferation was not affected by SRPX2 knockdown in GICs (Figure 4—figure supplement 1H). Variable results were obtained when self-renewal capacity was assessed by means of neurosphere extreme limiting dilution assay. Less neurospheres formed in the U3118 shRNA SRPX2 knockdown line...
at lower cell counts (6.25, 3.125, and 1.5625 cells per well) (Figure 4O, P), but this was not reproduced in the GIC19 shRNA SRPX2 knockdown lines (Figure 4—figure supplement 1I, J).

In conclusion, we found that BE-GICs gave rise to more invasive tumours in a xenograft model and that genes involved in migration/invasion are deregulated in these cells. Among these, SRPX2 plays a role in invasive properties of BE-GICs, raising the possibility that SRPX2 could be further explored as a potential therapeutic target for glioblastoma with a hypo-methylation bias and ACS enrichment.

**Glioblastoma enriched for an astrocytic signature display an altered immune landscape**

Pathway enrichment analysis performed on the lists of DEGs generated from the comparisons of BE-GICs versus nBE-GICs identified a deregulation of immune-related pathways – TGF-beta signalling and interferon-gamma signalling (Figure 3H), raising the possibility of differences in the tumour microenvironment of these glioblastomas. Among the 47 DEGs shared with the ACS identified when comparing BE-GICs and nBE-GICs (Figure 3—figure supplement 1I) was retinoic acid receptor responder 2 (RARRES2) – a chemoattractant, which binds to Chemerin chemokine-like receptor 1 (CMKLR1). RARRES2 was found to be significantly up-regulated in BE-GICs compared to nBE-GICs, in both our cohort and the HGCC cohort, and in non-G-CIMP tumour tissue relative to non-tumour brain tissue (Figure 5A and B and Figure 5—figure supplement 1A). Moreover, high expression of RARRES2 is correlated with a worse prognosis (Figure 5—figure supplement 1B). Significantly, RARRES2 is well known to play a role in inflammation (Mattern et al., 2014) and promoting the migration of plasmacytoid DC, macrophages, and NK-cells (Treeck et al., 2019). In scRNAseq data from Pombo Antunes et al., 2021, and Neftel et al., 2019, the receptor CMKLR1 is expressed in tumour-associated macrophages (TAMs) from newly diagnosed GBMs (Figure 5C, D), particularly in non-hypoxic TAMs (such as SEPP1-hi TAMs) as compared to hypoxic TAMs in recurrent glioblastomas (Figure 5E, F).

Therefore, we leveraged these datasets to analyse the immune composition of tumours with an enrichment for an astrocytic signature or increased proportion of astrocyte-like cells (Figure 3B, C). Both the myeloid and the lymphocyte clusters of the integrated scRNAseq data were selected and re-clustered, yielding various subpopulations of TAMs, dendritic cells (DC), mast cells, B, T, NK, and NK cells (Supplementary file 2, Supplementary file 3). The ACS/OPC pseudo-bulk score ratio had a significant positive correlation with the proportions of TAMs (in particular of SEPP1-hi moTAMs and cDC2) and of proliferating CD8 T cells (Figure 5). Conversely, a significant negative correlation was found between the proportion of cancer cells and the ACS/OPC pseudo-bulk score ratio (Figure 5I). Similar trends were observed when, utilising the single-cell resolution of the scRNAseq data, we correlated the proportion of TAMs, proliferating CD8 T cells, or cancer cells against the proportion of ACS-like tumour cells per patient (cells with higher ACS signature, compared to the two OPC signatures) (Figure 5J-L). The comparison of the proportion of ACS-like cancer cells against the fractions of monocytes and IFN-response CD8 T cells per patient also yielded a significant positive correlation. Furthermore, we show that these results were reproduced, when the signatures from Neftel et al., 2019, were used to determine the proportions of astrocyte-like cancer cells per patient and the latter were correlated to the proportions of immune and cancer cells in each tumour (Figure 5M-O). Staining for CD68 in the FFPE tumour tissue from our cohort found a trend for an increased percentage of CD68+ cells in tumours of BE-GICs relative to nBE-GIC tumours (Figure 5—figure supplement 1C). Finally, the opposite trends were observed when we correlated the proportion of TAMs, proliferating CD8 T cells, or cancer cells against the proportion of OPC and NPC-like cancer cells (as determined by Neftel et al., 2019, signatures), however not all of the findings were statistically significant (Figure 5—figure supplement 1D-I).

In conclusion, a significant up-regulation of RARRES2 is identified in BE-GICs, and an increased proportion of TAMs and CD8 proliferative T cells is found in tumours with a larger fraction of astrocyte-like tumour cells. This may indicate that the composition of the TME is different in tumours with an astrocytic signature enrichment.
Figure 5. GBM enriched for an astrocytic signature display an altered immune landscape. (A) Expression of RARRES2 in BE-GiCs (N=8) and nBE-GiCs (N=12) in our cohort, determined by RNAseq. (B) Expression of RARRES2 in BE-GiCs (N=13) and nBE-GiCs (N=6) in the HGCC cohort. (C) UMAP of monocyte and tumour-associated macrophage (TAM) cell clusters from the Antunes et al. (Tarazona et al., 2015) newly diagnosed glioblastoma tumour data; the cells are coloured by cell type. (D) Expression of CMKLR1 across different immune cell type clusters from panel (C). (E) UMAP of monocyte and
TAM clusters from the Antunes et al. (Tarazona et al., 2015), recurrent glioblastoma tumour data; the cells are coloured by TAM subtype. (F) Expression of CMKL1 across different TAM subtype clusters from panel (E). Scatter plot, comparing the ratio of the astrocyte composite signature (ACS) and the mean OPC pseudo-bulk enrichment scores, and the proportion of TAM cells (G), CD8 proliferative T cells (H), and cancer cells (I) from the same tumour. Scatter plot, comparing the proportion of ACS-enriched cancer cells and the proportion of TAM cells (J), CD8 proliferative T cells (K), and cancer cells (L) from the same tumour, corresponding to the dataset from (G–I). Scatter plot, comparing the proportion of AC-enriched and the proportion of TAM cells (M), CD8 proliferative T cells (N), and cancer cells (O) from the same tumour, corresponding to the dataset from (G–I). Spearman’s rank correlation coefficient and the corresponding p-value are noted on each scatter plot. The blue lines represent smoothed conditional means using general linear model, while the grey areas on the plots denote the confidence interval around the smooth (using the geom_smooth function of ggplot2).

The online version of this article includes the following source data and figure supplement(s) for figure 5:

Source data 1. Source data for Figure 5.

Figure supplement 1. scRNA analysis of the TME composition in glioblastoma enriched for an astrocytic signature.

Figure supplement 1—source data 1. Source data for Figure 5—figure supplement 1.

Discussion

We have identified a novel DNA hypo-methylation bias in a proportion of glioblastoma, which is ontogenetically linked to astrocyte progenitors. Hypo-methylated loci are enriched for binding motifs of TFs known to be involved in astrocyte differentiation, and DEGs and miRNAs known to play a role in astrocyte lineage commitment and differentiation were detected in B-GICs. At a functional level, BE-GICs are characterised by increased invasion in vivo, enhanced SRPX2-regulated invasive properties in vitro, and an altered immune microenvironment.

Altering changes of the DNA methylene have been previously described in genetically defined high-grade gliomas. In particular, the G-CIMP hyper-methylator phenotype characterises IDH-mutant gliomas (Tahiliani et al., 2009), where mutated IDH gains the ability to convert α-KG to 2-HG, which functions as an oncometabolite whilst also being a competitive inhibitor of α-KG-dependent dioxygenases such as TET enzymes (Tahiliani et al., 2009). Consequently, IDH-mutant glioblastoma cells accumulate DNA methylation as TET enzymes are inhibited from removing methylation marks. A hypo-methylation bias has been previously found also in the paediatric H3 G34 mutant glioma subgroup (Sturm, 2012), where mutations in the histone H3 variant H3.3 (H3F3A) block SETD2 binding, leading to loss of H3K36 methylation, which in turn is linked to DNA methylation (Rose and Klose, 2014). Alternatively, mutation and loss of ATRX, which is consistently found in G34 mutant glioblastoma, could contribute to hypo-methylation at highly repeated sequences such as rDNA (Gibbons et al., 2000). The DNA hypo-methylation bias described here is found in a proportion of IDH-wildtype glioblastomas, which are enriched for an astrocytic signature. The pan-cancer analysis of DNA methylomes, published in 2018 (Saghafinia et al., 2018), reported that a proportion of IDH-wildtype gliomas exhibited high percentages of hypo-methylated loci, which correlated with a stemness signature (Malta et al., 2018), based on hypo-methylation of specific loci enriched for the SOX2-OT4 binding motif. We did not find enrichment for the SOX2-OT4 motif in the hypo-methylated DMRs from B-GICs, but rather an enrichment for TF binding sites known to play a role in glial/astrocyte differentiation, which is consistent with the enrichment for an astrocytic signature. Importantly, we have shown that the hypo-methylation bias is not induced in GIC by in vitro culture as it was confirmed in the respective tumour tissue. Likewise, we have taken advantage of publicly available single-cell transcriptome datasets to confirm that enrichment for our bespoke astrocytic signature as well as published astroglioma signatures (Neftel et al., 2019) is found in a proportion of GBM.

Of particular interest was the finding of an enrichment for members of the NFI family in the hypo-methylated DMRs from B-GICs as previous studies have shown that astrocyte differentiation requires Nfia-induced demethylation of key astrocyte lineage specifying genes (Sanosaka et al., 2017; Namihira et al., 2009). In fact, Sanosaka et al., 2017, showed that the methylome underpins the differentiation potential of NSCs rather than gene expression itself. They found that E11.5 embryonic mouse NSCs were lineage-restricted and only giving rise to neurons, whilst E18.5 NSCs had an increased proportion of hypo-methylated loci and were multipotent – being able to give rise to glial and neuronal lineages. Furthermore, this study also showed that DMRs with reduced methylation (hypo-methylated) in E18.5 NSCs as compared to E11.5 NSCs are enriched for NFI binding sites, and that this gene family was responsible for the loss of DNA methylation and gain of multipotency for
the glial lineage. It is intriguing that these previous studies may provide an interpretative framework as to why we find a positive correlation between the hypo-methylation bias and ACS enrichment. It is conceivable that B-GICs may arise from a neural progenitor population that has undergone priming for glial differentiation, for example by the NFI TF family. Other TF binding sites we found enriched in hypo-methylated loci are also known to be involved in glial/astrocyte differentiation, such as ETV4 (Ghosh et al., 2016; Tiwari et al., 2018) and PLAGL1, the latter by transactivating Socs3, a potent inhibitor of pro-differentiative Jak/Stat3 signalling, thereby preventing precocious astroglia differentiation (Schmidt-Edelkrout et al., 2013). We found a significant enrichment for genes of the ACS in the DEGs between B-GICs and nB-GICs in both our and the HGCC datasets. Likewise, the five differentially expressed miRNAs identified in this comparison – miR-4443, miR-1275, miR-196, miR-5100, and miR-1268, which have been previously linked to cancer or glioblastoma pathogenesis (Mai et al., 2019; Gao et al., 2019; Ma et al., 2012; Yang and Wang, 2016; Wang et al., 2017b), have also been linked either directly or indirectly to glial differentiation. These include miR-196 known for its regulatory role of Homeobox (HOX) genes (Sehm et al., 2009) in both a healthy and malignant developmental context and miR-1275 previously shown to be involved in glial lineage specification (Mai et al., 2019; Katsushima et al., 2012). Taken together, the results of the binding motif analysis and of the differential expression analysis raise the possibility that BE-GICs arise from a neural progenitor, which has undergone glial/astrocyte priming. Overexpression of NFI family members in nB-GICs will be required to assess whether changes in DNA methylation and gene signature enrichment can be elicited, or whether this enrichment is a consequence of the hypo-methylation bias. Alternatively, disruption of the NFI binding motifs across the genome, for example by means of CRISPR-Cas9 system (Ran et al., 2013) could be carried out to assess the effect on DNA hypo-methylation and gene signature enrichment.

We noted that whilst the hypo-methylation bias was retained in bulk FFPE tumour tissue, the ACS enrichment was not. It is possible that this is due to the lower RNA quality, as compared to excellent DNA quality obtained from FFPE material, which limit the transcriptome characterisation. It is also possible that the transcriptome is more dynamic and prone to change, and so for example whilst GICs pass on their epigenetic signature to daughter cells when they proliferate, the regulation of their transcriptome may not be equally inherited by the daughter cells. Finally, the cellular heterogeneity, including the tumour microenvironment, could also be obscuring the astrocyte signature enrichment in the parental tumour.

Importantly, when comparing DEGs between BE-GICs and nB-GICs, a predicted impact on cell movement/invasion was identified. In keeping with this prediction, xenografts generated from BE-GICs were found to grow more invasively as compared to those generated by nB-GICs. This is of particular interest in glioblastoma, given the diffusely infiltrative growth of these tumours, which plays a significant role in limiting the effectiveness of the current therapies. Among the genes deregulated, SRPX2 stood out as it has been previously shown to be associated with poor prognosis, and to promote tumour progression and metastasis in primary GICs (Tang et al., 2016). Indeed, we show that silencing of this gene leads to impaired invasion in two BE-GIC lines in vitro assays, although in vivo validation will be required to substantiate this finding.

The immune microenvironment plays a crucial role in tumour pathogenesis, including glioblastoma (Pombo Antunes et al., 2021; Dumas et al., 2020). We have identified a significant deregulation of genes involved in immunomodulatory pathways in BE-GICs and analysis of scRNAseq datasets of glioblastoma has confirmed an altered immune landscape in glioblastoma with an ACS signature enrichment. The significant correlation between the ACS signature enrichment and the number of TAMs is of particular interest given the up-regulation of RARRES2 in BE-GICs and the role of TAMs in glioblastoma invasion (Andersen et al., 2021). Interestingly, a SEPP1-hi phenotype was observed in these TAMs corresponding to an anti-inflammatory phenotype (Pombo Antunes et al., 2021), which raises the possibility that they could play a pro-tumourigenic role in these glioblastomas.

A recent methylome analysis of various tumour types has found that global methylation loss correlates with increased resistance to immunotherapy and immune evasion signatures (Jung et al., 2019), hence the identification of GBMs with these features could have important implications in patient stratification for immunomodulatory treatments.
Materials and methods

Tissue culture

We have previously described a novel experimental pipeline, SYNGN, to derive GICs and EPSCs as well as iNSCs from patients who underwent surgical resection of glioblastoma (Vinel et al., 2021). The use of human tissue samples was approved by the National Research Ethics Service (NRES), University College London Hospitals NRES Project ref 08/0077 (S Brandner); Amendment 1 17/10/2014. In brief, at the time of operation, tumour tissue and a thin strip of the dura mater were obtained. Fibroblasts were isolated from the dura mater, propagated, and reprogrammed to generate EPSCs, which were further differentiated into iNSCs, iAPCs, and iOPCs. All media recipes can be found in Supplementary file 4a-e.

GICs were cultured on laminin (Sigma Cat. #L2020) coated tissue culture plates at 37°C, 5% CO₂. Cells were maintained in Neurocult media (Stem Cell Technologies Cat. #05751) supplemented with 1% penicillin/streptomycin solution (Sigma Cat. #P4458), Heparin (Stem Cell Technologies Cat. #07980), EGF (Peprotech Cat. #AF-315-09-1MG) and FGF (Peprotech Cat. #AF-100-18B-50UG) and passaged once they reached 80–90% confluence. GICs from the HGCC cohort were cultured on Poly-L-Ornithine (Sigma Cat. #P3655) and laminin-coated plates and maintained in media termed HGCC Media (Supplementary file 4a), supplemented with EGF and FGF, and passaged in the same manner as GICs from our own cohort. Separate passages of the same GIC line were considered to be biological replicates.

Dura-derived fibroblasts were reprogrammed into EPSCs as previously published (Wilkinson et al., 2019; Yang et al., 2017), EPSCs were then further differentiated into iNSCs with a Gibco commercially available kit (Vinel et al., 2021) (Gibco Cat. #A1647801). iNSCs were cultured on GelTrex (Gibco Cat. #A1413302) coated tissue culture plates and maintained in Neural Expansion media (Supplementary file 4b) at 37°C, 5% CO₂. iNSCs were passaged once they reached 80–90% confluence.

HEK293T cells were cultured in adherent conditions and maintained in IMDM media (Gibco Cat. #12440061) supplemented with 10% foetal bovine serum (FBS) (Gibco Cat. #10500064) and 1% penicillin/streptomycin solution, provided with the media. From day 2 onwards, media was changed every 48 hr for 20–30 days. At 80–90% confluence, the cells were passaged back to the starting seeding density (1.5×10⁴ cells/cm²), or at an approximate ratio of 1:6. Cells were detached using Accutase, and always cultured in the same Astrocyte media on GelTrex. Cell pellets were collected at three different timepoints throughout the differentiation process, when cells were confluent and passaged; approximately at days 10, 20, and 30. Differentiated astrocytes could be cryopreserved using Astrocyte media supplemented with 10% DMSO, or commercially available SynthFreeze (Gibco, Cat. #A1254201).

iAPC and iOPC generation

Differentiation of iNSCs into iAPCs was adapted from published protocols (Tcw et al., 2017). Differentiation was initiated on day –1, by seeding dissociated iNSCs at 1.5×10⁴ cells/cm² density on GelTrex-coated plates in Neural Expansion media. On day 0 Neural Expansion media was changed to Astrocyte media (ScienCell: Cat. #1801) supplemented with 2% FBS, astrocyte growth supplement (AGS), and penicillin/streptomycin solution, provided with the media. From day 2 onwards, media was changed every 48 hr for 20–30 days. At 80–90% confluence, the cells were passaged back to the starting seeding density (1.5×10⁴ cells/cm²), or at an approximate ratio of 1:6. Cells were detached using Accutase, and always cultured in the same Astrocyte media on GelTrex. Cell pellets were collected at three different timepoints throughout the differentiation process, when cells were confluent and passaged; approximately at days 10, 20, and 30. Differentiated astrocytes could be cryopreserved using Astrocyte media supplemented with 10% DMSO, or commercially available SynthFreeze (Gibco, Cat. #A1254201).

iNSCs were differentiated into iOPCs using a published protocol (Douvaras and Fossati, 2015), commencing from iPSCs and achieving fully mature oligodendrocytes at 95 days. Here, the protocol was started from iNSCs, equivalent to day 8 of the Douvaras-Fossati protocol, which were induced into OPCs up to day 75, when the original authors reported emergence of immature O4⁺ oligodendrocytes. On day 0 of our protocol (day 8 of the Douvaras-Fossati protocol) Neural Expansion media was removed, and iNSCs cultured in N2 media (Supplementary file 4c) with 100 nM RA and 1 µM smoothened agonist (SAG) added freshly each day. Media was then changed daily with fresh RA and SAG until day 4, at which point cells became over-confluent and were detached and placed in N2B27 Media (Supplementary file 4d) with freshly added RA and SAG. A series of scratches were made with a cell scraper vertically, horizontally, and diagonally across each well, and the contents of a single well transferred into eight wells of an ultra-low attachment 24-well plate (Corning Cat. #3473), with extra N2B27 media. Aggregates were then cultured in suspension for a further 8 days, with media changed every 48 hr. On day 12 of the protocol N2B27 media was replaced with PDGF media (Supplementary file 4e).
file 4e), and aggregates were cultured for a further 10 days, with media replaced every 48 hr. On day 22 of the protocol aggregates were plated onto Poly-L-Ornithine and laminin-coated plates and were cultured adherently until day 67 of the protocol, with PDGF media changes every 48 hr.

Two independent differentiations of iAPCs and iOPCs from iNSCs were considered to be biological replicates. For iNSCs two independent differentiations from iPSCs were considered to be biological replicates.

**Proliferation assay**

For the comparison of iNSCs and iAPCs cells were seeded at $2 \times 10^4$ cells per well of a 24-well plate (CytoOne Cat. #CC7682-7524), whilst for the comparison of GIC lines cells were seeded at $1 \times 10^4$ cells per well of a 24-well plate. Then, at selected timepoints (every 24 hr) starting from day 1 or day 2, cells from each well were individually detached using Accutase, then centrifuged individually (1200 rpm) at 4°C for 5 min. At least three wells were detached and counted at each timepoint to generate technical triplicates. After detachment and centrifugation, cell pellets were resuspended in 100 µL DPBS and 10 µL was mixed with 10 µL of Trypan Blue (Sigma Cat. T8154-100ML) and live cells counted using a haemocytometer.

**Invasion assay**

Transwell inserts with 8.0 µm pores (Sarstedt Cat. #89.3932.800) were placed into wells of a 24-well plate and coated with 100 µL of GelTrex. A total of 100,000 cells were then seeded into the transwell insert in 200 µL and 700 µL of normal growth media was added to the bottom of the well. Cells were then incubated in normal growth conditions for 24 hr, at which point cells on the inside of the transwell were removed using a cotton bud dampened with DPBS. Once cells inside the transwell were removed, cells on the bottom of the transwell were fixed using methanol, pre-chilled to –20°C, for 5 min at room temperature. After fixation, the bottom of the transwell was washed twice for 5 min using DPBS. The membrane of the transwell was then cut out and mounted onto a microscopy slide with mounting media including DAPI (Vectorlabs Cat. #H-2000). Transwell membranes were then analysed at the microscope and five representative images of nuclei on each membrane captured. For each biological group and replicate (different passages of cell lines), three technical replicate membranes were imaged. Finally, the number of whole nuclei in each image field were counted, using ImageJ software (Version 1.51m9), to ascertain how many cells migrated across the membrane.

**Neurosphere extreme limiting dilution assay**

On day 0 of the assay, cells were seeded at a maximum cell density of 25 cells per well of a round bottom ultra-low attachment 96-well plate (Corning Cat. #7007). Cells at this density were then serially diluted 1:2 a total of four times to give five cell densities in total – 25, 12.5, 6.25, 3.125, and 1.5625 cells per well. For each biological replicate (different passages of cell lines), 12 technical replicates of each cell density were performed (12 separate wells). Cells were then incubated for 14 days with media changes every 48 hr, after which time the presence of neurospheres was assessed and counted for each well. To be considered a neurosphere, cells had to form 3D spherical clusters with smooth and defined edges and had to be greater than two cells in size. Results were analysed using the extreme limiting dilution analysis tool (Hu and Smyth, 2009), where the log proportion of negative cultures is plotted against the number of cells seeded, with a trend line indicating the estimated active stem cell frequency. The statistical significance of the differences between the estimated active stem cell frequencies of different cell lines was also tested using a chi-squared test as part of the analysis tool (Hu and Smyth, 2009).

**Animal procedures**

All procedures were performed in accordance with licenses held under the UK Animals (Home Office Guidelines: animals Scientific Procedures Act 1986, PPL 70/6452 and P78B6C064 Scientific Procedures) Act 1986 and later modifications and conforming to all relevant guidelines and regulations. Orthotopic xenografts were performed on 8- to 12-week-old NOD SCID CB17-Prkdcscid/J mice (purchased from The Jackson laboratory) under anaesthesia with isoflurane gas and 5 × 10^5 primary human GIC in 10 µL PBS were slowly injected with a 26-gauge Hamilton syringe needle into the right cerebral hemisphere with the following coordinates from the bregma suture: 2 mm posterior, 2 mm
lateral, 5 mm deep, 10° angle. After the injection, scalps were cleaned with ethanol swab to remove any remaining cells and sutured with 4-0 Coated Vicryl Suture (Ethicon). After the surgery, mice recovered on a heatmap until they were fully awake. For the 5 days following surgery, mice were checked twice a day, then once a day and body weight was monitored once a week. Mice were kept on tumour watch until they developed brain tumour clinical symptoms and were then euthanised by neck dislocation and brains were harvested for histology analysis.

**DNA and RNA extraction**

Cells used for qPCR analysis were pelleted and frozen at –80°C before RNA extraction. RNA was extracted by following the standard protocols of either Qiagen RNeasy Mini or Micro kits (Cat. #74104/74004). Some cell pellets were processed using Norgen Biotek RNA/DNA/Protein Purification Plus Kit (Cat. #47700), which allows genomic DNA, total RNA, and protein to be isolated from a single sample. RNA to be sent for RNAseq, and DNA to be sent for DNA methylation array, were prepared using the Norgen Biotek kit, according to the manufacturer’s instructions.

**Reverse transcription and qPCR**

Reverse transcription reactions were carried out by first mixing 1 µL random primers (Invitrogen Cat. #48190011), 500 ng RNA and ddH₂O up to 10 µL, primers were then annealed by heating to 65°C for 5 min, then 4°C for 5 min. Then 4 µL 5× FS Buffer, 1 µL 0.1 M DTT, 0.5 µL SuperScript III Reverse Transcriptase (Invitrogen Cat. #18080044), 1 µL 10 mM dNTP mix (Invitrogen Cat. #18427-013), and 3.5 µL ddH₂O were added to this reaction mixture.

qPCRs were carried out using Applied Biosystems Syber Green qPCR Master Mix (Cat. #4309155). Each reaction contained 2 µL of 2.5 ng/µL cDNA (5 ng total), 0.48 µL of 10 µM forward and reverse primer mix, 3.52 µL ddH₂O, and 6 µL of Syber Green Master Mix (12 µL total reaction volume). All qPCRs were run on an Applied Biosystems 7500 Real-Time PCR System or StepOnePlus Real-Time PCR System. A full list of primers and their sequences used throughout this project can be found in Supplementary file 4f.

**Flow cytometry and FACS**

Primary and secondary antibodies used for flow cytometry and fluorescent activated cell sorting (FACS) staining are listed in Supplementary file 4g. Samples stained with unconjugated primary antibodies were incubated with species reactive secondary antibodies with various fluorophores conjugated. Samples for flow cytometry analysis were analysed using a BD LSRII Analyser, samples for FACS were processed using a BD FACS Aria Sorter.

For FACS of live iOPCs, cells were dissociated by removing culture media, adding FACS buffer (1:200 BSA Sigma Cat. #A3912, 1:250 EDTA 0.5 mM Ambion Cat. #AM9262, in DPBS) and homogenising the cells into a single-cell suspension. As the culture contained large aggregates, the cell suspension was passed through a 100 µm size filter. Cells were then counted and centrifuged at 1500 rpm for 5 min at 4°C followed by dispensing 100 µL of a 5×10⁶ cells/mL suspension per tube for staining. Prior to staining cells were incubated in anti-CD16/32 FcR block (diluted 1:200 in FACS buffer) for 15 min at 4°C, washed and then incubated with conjugated or unconjugated primary antibodies for 30 min at 4°C. Staining was carried out with either single antibodies or combinations of antibodies. Finally, cells were pelleted and resuspended in DPBS before FACS.

For flow cytometry analysis of cell samples, cells were harvested, resuspended in FACS buffer, and blocked with FcR blocker in the same manner as for FACS analysis. Extracellular antibodies were first incubated with samples for 30 min at 4°C, followed by washing and resuspension in a fixable viability dye diluted 1:200 in DPBS and incubated for 20 min at 4°C. After further washing, cells were then fixed for 20 min at 4°C in 4% PFA diluted in a 1:1 ratio with FACS buffer. For the staining of intracellular targets, after fixation the cells were permeabilised using methanol for 5 min at room temperature and incubated with antibodies diluted in methanol for 20 min at room temperature. Finally, samples were washed in FACS buffer and resuspended for analysis.

**Immunocytochemistry**

All cells analysed via immunocytochemistry were washed in DPBS and fixed by treatment with 4% paraformaldehyde for 15 min, then washed in DPBS for 5 min, three times. Fixed cells were stored
at 4°C in DPBS until staining. Cells were then permeabilised and blocked followed by staining with primary antibodies. Primary antibodies and the dilutions used in this study can be found in Supplementary file 4g. After primary antibody incubation, overnight at 4°C or 3 hr at room temperature, samples were washed in DPBS, and stained with species reactive secondary antibodies conjugated to various fluorophores for 1 hr at room temperature. After washing once again in DPBS, sample slides were then mounted using Fluoroshield mounting media with DAPI and sealed using nail varnish.

**Immunoblotting**

Cell samples used for protein extraction were first pelleted by centrifugation, at full speed, for 5 min, then snap-frozen using dry ice and stored at –20°C until extraction. Protein was extracted from cell pellets by resuspending pellets in RIPA lysis buffer (25 mM Tris-HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with protease inhibitors (Santa Cruz Cat. SC-24948A), samples were then left to incubate on ice for 30 min. After incubation samples were centrifuged, at full speed, for 15 min, at 4°C, and the supernatant collected.

Protein concentration was determined using BCA assay (Thermo Cat. #23227) performed as per the manufacturer’s instructions. Concentration of protein samples was then determined by interpolating the absorbance values of the unknown samples with a standard curve of known protein concentrations.

An equal amount of protein was then loaded into a 4–12% acrylamide gel (Invitrogen Cat. #NP0322BOX). Proteins were separated in SDS-PAGE (Thermo Fisher Cat. #NP-0001) and blotted onto a nitrocellulose membrane (GE Healthcare Cat. #10600002). Membranes were then blocked with 5% non-fat milk (Santa Cruz Cat. #SC-2325) in Phosphate Buffered Saline-Tween (PBS-T) (0.1% Tween 20 [Sigma Cat. #P9416-100ML] in PBS) for 1 hr at room temperature and then incubated with primary antibodies at 4°C overnight. The Supplementary file 4g summarises primary antibodies and their dilutions used in this study. After incubation of primary antibody membranes were washed three times for 5 min in PBS-T and then incubated, at room temperature, with the species appropriate peroxidase-conjugated secondary antibody at a dilution of 1:5000 for 1 hr. Membranes were further washed three times for 5 min in PBS-T before being visualised using ECL kit (GE Healthcare Cat. #RPN2232) and ChemiDoc Imaging System (Bio-Rad). Quantification of the protein expression was measured by densitometric analysis performed with ImageJ software (Version 1.51m9).

**Enzyme linked immunosorbent assay**

Quantification of secreted proteins and chemokines such as interleukin-6 (IL-6) was performed using an enzyme linked immunosorbent assay (ELISA). Cells were cultured, prepared, and treated as already described, and after treatment growth media supernatant was collected for analysis by ELISA. Upon collection, supernatant was filtered using 0.22 µm syringe filter (Santa Cruz Cat. #SC-358812) and snap-frozen using dry ice, followed by storage at –80°C until analysis. The ELISA was then performed as per the manufacturer’s instructions (BD Bioscience IL-6 ELISA Cat. #555220), and concentrations determined by interpolating absorbance values of samples using a standard curve.

**shRNA lentivirus production and transduction of cell lines**

Lentivirus particles were produced using HEK293T cells. To produce shRNA lentivirus, a Lipofectamine 3000 (Invitrogen Cat. #L3000-015) transfection protocol was used. Transfection was carried out as per the manufacturer’s standard protocol, by forming DNA-lipid complexes which were then incubated on cells for 6 hr followed by addition of packaging media for lentivirus harvesting. Packaging media consisted of OptiMem reduced serum media supplemented with Glutamax (Gibco Cat. #51985-034), with 1 mM sodium pyruvate (Gibco Cat. #11360-039) and 5% FBS. Twenty-four hr post transfection, media was harvested from HEK293T cells and stored at 4°C, 10 mL of fresh packaging media was added. Fifty-two hr post transfection media was harvested once again and mixed with media previously harvested. Harvested supernatant was then centrifuged at 2000 rpm for 5 min to remove cell debris, then filtered through a 0.44 µm filter (VWR Cat. #514-0329). To precipitate and concentrate lentiviral particles, 5x polyethylene glycol (PEG) (Sigma #89510-1KG-F) was prepared by mixing 200 g PEG, 12 g NaCl (Fisher Cat. #5/3166/60) and 1 mL of 1 M Tris (pH 7.5) (PanReac AppliChem Cat #A4263,0500) then ddH₂O added to a total volume of 500 mL, pH of PEG was further adjusted to 7.2, and then autoclaved before use. 5× PEG was then added to harvested supernatant to give a final
concentration of 1× and then incubated at 4°C overnight. The following day harvested supernatant mixed with PEG was centrifuged at 1500 g for 30 min at 4°C, supernatant was removed and spun again to remove excess supernatant. The lentiviral pellet was then resuspended in an appropriate amount of DPBS, aliquoted and stored at −80°C until use.

Harvested virus was titrated to determine the transforming units per mL (TU/mL) for each volume of virus used during titration. Cell lines were infected overnight with the stated multiplicity of infection (MOI) of lentiviral particles. The TU/mL that achieved 5–30% of fluorescent tag positive cells during lentivirus titration was selected for the calculation of the MOI. The following day after infection with lentivirus, media was changed, and the cells were left to recover. Once confluent the cells expressing the desired construct were then purified by Puromycin selection or FACS, if transduced with constructs with a Puromycin resistance gene or fluorescent tag.

Glycerol stocks of competent bacteria containing shRNA plasmids, for lentivirus production, were purchased from Horizon Discovery Dharmacon. To obtain plasmid for lentiviral production, a small of amount of glycerol stock was extracted and added to LB broth (Sigma Cat. #L3522) supplemented with the relevant antibiotic, and grown up in large liquid culture, overnight at 37°C. Following this, plasmid DNA was isolated and purified using the Qiagen Maxi Prep kit (Qiagen Cat. #12963). Details of each shRNA plasmid constructs can be found in Supplementary file 4h.

**DNA methylation data processing**

DNA used for methylation arrays was extracted and prepared as described above. Two biological replicates of each patient-matched GICs, iNSCs, iAPCs, and iOPCs were sent for DNA methylation array. DNA was assayed on the Illumina Infinium Methylation EPIC array (over 850,000 probes). Raw data was imported into an R workspace (R Version 3.5.0) and all analysis therein performed using the RStudio environment (Version 1.1.453). Raw data from the array was first processed using the ChAMP (Tian et al., 2017; Morris et al., 2014) (Version 2.12.4) R package to remove any failed detections and flawed probes. Along with data, metadata was also imported and used to help perform analysis. After this initial processing, data were then further processed and normalised using the Subset-quantile within array normalisation (SWAN) algorithm (Maksimovic et al., 2012). All methylation data used for further analysis such as differential methylation, PCA, or heatmap and dendrograms were SWAN normalised data.

After initial processing of DNA methylation array data, as described above, DMRs and genes were identified. To do so, output data from the SWAN normalisation algorithm in the form of beta values were imported into an R workspace and different datasets merged into a single dataset with the only probes that were common to all samples. After initial data processing, the R package DMRcate (Peters et al., 2015) (Version 1.18.0) was then used to first identify DMRs and then the corresponding genes. The minimum number of contiguous (or consecutive) differentially methylated probes per region to be called a DMR was set to 6, the beta cutoff was set to 0.3, and as the lambda parameter (bandwidth) was set to 1000, the scaling factor (C) was set to 2 as per the authors’ recommendations. Unless otherwise stated here, all other parameters were set to their respective default settings.

**RNAseq data processing**

RNA used for RNAseq was extracted and prepared as previously detailed. RNA samples from two biological replicates of patient-matched iAPCs, iNSCs, and GICs was of sufficient quality and quantity (minimum 1000 ng total mass at concentration of 50 ng/µL with 260:280 and 260:230 ratios equal to ~2) as to perform Poly-A library preparation followed by sequencing using the Illumina HiSeq 4000 platform at 75 PE. For sequencing of miRNAs, total RNA extracted as already outlined was prepared using the NEBNext smallRNA kit for Illumina (E7330L). In some cases where insufficient quantities of RNA were isolated from single passages of cells, RNA from two passages were combined. iOPC samples yielded very low quality and quantity of RNA after extraction and therefore samples were not suitable to be prepared using the Poly-A library preparation method. Instead, two biological replicate iOPC samples, for each patient, were prepared using the SmartSeq2 library preparation method and sequenced using the Illumina HiSeq 4000 platform at 75 PE.

The raw RNAseq data generated was processed in multiple ways depending on the output of the analysis. FastQC (Version 0.11.5) (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) was used to perform quality control of the raw data, to check the Phred score, the GC content distribution,
and the duplication levels, then the TrimGalore tool (Version 0.4.5–1) (DOI 10.5281/zenodo.5127898) was used to remove low-quality reads (Phred score <20) and residual adapters. For the use of differential expression analysis raw data was processed using the STAR gapped alignment software (Dobin et al., 2013) (Version 2.7.0), which generated gene counts. The reference genome used for alignment was Ensembl GRCh38 (release 90). Following alignment, prior to differential gene expression analysis, further processing of the STAR output data was performed. Genes with a counts per million (CPM) value <1, in a minimum of half of the samples per group (i.e., GIC or iNSC) plus one, were removed. DEGs were identified using the R package: EdgeR (Robinson et al., 2010; McCarthy et al., 2012) (Version 3.24.3) with the thresholds that the minimum absolute log fold change (logFC) in gene expression was 2 and the false discovery rate was less than 0.01. EdgeR analysis was performed using two statistical tests provided by the package – the likelihood ratio test (glmFit) and the quasi-likelihood ratio test (glmQLFit), however all gene lists used in further downstream analysis were generated from the more conservative glmQLFit test, unless otherwise stated.

For the differential gene expression analysis of GICs from the HGCC cohort, microarray data that had been pre-processed (normalised and Combat batch adjusted) was used. Differential gene expression analysis was then performed in an R workspace using the RStudio environment and limma package (Law et al., 2014) (Version 3.40.6). Linear modelling was implemented by the lmFit function and the empirical Bayes statistics implemented by the eBayes function and DEGs with a p-value < 0.05, and logFC >0.5, were selected by the topTable function. Volcano plots depicting the logFC and statistical significance of DEGs, from analysis of both microarray data and RNAseq data, were generated using the R package EnhancedVolcano (Version 1.5.10).

To generate heatmaps, dendrograms and perform PCA (all detailed below), a different approach was used to process raw RNAseq data. Alignment was instead performed using pseudoalignment package Salmon (Patro et al., 2017) (Version 0.13.1), with the output being transcript expression level, which were then pooled to give gene level expression estimates expressed as transcripts per million (TPM) (Durinck et al., 2009; Durinck et al., 2005). This unit is normalised for library size and transcript length. The reference genome used for Salmon alignment was Ensembl GRCh38 (release 90).

**PCA, heatmaps, and dendrograms**

PCA was performed on both methylation array data and RNAseq data to validate the sequencing data. Output data from the pseudoalignment package Salmon (TPM counts) were used for PCA of RNAseq data, and beta values from SWAN normalised data we used for PCA of methylation array data. Prior to PCA, data were filtered to include only the most variable methylation probes or genes, the exact number used for each figure is stated in the relevant figure legend. The R package NOIseq (Tarazona et al., 2015; Tarazona et al., 2011) (Version 2.26.1) was used to perform PCA and then the results plotted, using R packages ggplot2 (Wickham, 2009) (Version 3.1.1) (for two-dimensional plotting of two PCs) or plotly (Version 4.9.0) (for three-dimensional plotting of three PCs).

Heatmaps and dendrograms were generated using both DNA methylation and RNAseq data. The RNAseq data used was the output from the pseudoalignment package Salmon (gene expression data in units of TPM). DNA methylation data used was beta values from SWAN normalisation. RNAseq data was filtered prior to analysis by removing genes with a TPM value <1 and the number of samples in each group (i.e., GIC or iNSC) that must express each gene to half the group size plus one. After this initial filtering, only the most variable genes were used in the analysis, with the exact number stated for each figure. In general, the Euclidean clustering method and complete distance methods were used as part of the standard heatmap.2 function in R.

**Gene signature analysis**

Gene signature analysis was performed using ssGSEA method. In order to calculate ssGSEA enrichment scores for our samples, the R package GSVA (Hänzelmann et al., 2013) (Version 1.30.0) was used. The gene level expression estimates output, expressed as TPM, from alignment using the Salmon (detailed earlier) were used as the input for this analysis. As well as gene expression data, gene lists or signatures were also required, and all gene lists/signatures were formatted as Ensembl gene IDs.
The oligodendrocyte gene signatures used here were taken from a published study by McKenzie et al., 2018. The ACS was manually generated by compiling multiple astrocytic gene signatures into one coherent gene signature. Astrocytic gene signatures were first found in the xCell bioinformatics tool (Aran et al., 2017): xCell is a tool used to de-convolute a sample composed of a mixture of cell types into its respective cell types, based on gene signatures curated and validated by the authors. Multiple data sources were used to generate gene signatures for as many cell types as possible, and the authors generated a gene signature for a given cell type from each data source, meaning more than one gene signature was generated for each cell type. For example, three data sources contained astrocyte expression data, and thus two astrocyte signatures were generated from each data source, meaning there were six signatures for the tool to use to de-convolute mixed samples. In this present study, we have taken these six astrocyte signatures used by the xCell tool and merged them into one coherent signature. The ACS and the oligodendrocyte signatures used in this study can be found in Supplementary file 4.

Motif analysis using Homer
Identification of enriched binding motifs in genomic regions was performed using Homer Hypergeometric Optimization of Motif EnRichment (Version 4.11, 10-24-2019) (Heinz et al., 2010). The tool findMotifsGenome.pl was used to perform de novo search as well as to check the enrichment of known motifs, in the context of the latest human genome annotation (hg38). Homer searched significantly enriched motifs (p-value <0.05) with a length spanning a wide range of standard values (6, 8, 10, 12, 15, 20, 25, 30, 35, 40, 45, 50 bp) in a region of default size (200 bp) at the centre of each sequence. Following the Homer guidelines (http://homer.ucsd.edu/homer/index.html), the option -mask was used, to minimise the bias towards long repeats in the genome, and the maximum number of mismatches allowed in the global optimization phase has been set to 3, to improve the sensitivity of the algorithm. Other settings have been left as default, such as the distribution used to score motifs (binomial). Finally, a scoring algorithm assigned a ranked list of best matches (known motifs or genes) to each de novo motif, to inform the biological interpretation of the results.

Image analysis
Whole-slide images (WSI) of immunostained sections of xenografts derived from GICs lines were analysed using QuPath (Bankhead et al., 2017). A machine learning-based pixel classifier was manually trained on a subset of WSI to detect tissue sections and vimentin immunostaining and create corresponding annotations. The trained pixel classifier was then applied to the whole set of WSI. Prior to detecting vimentin immunostaining using the pixel classifier, tissue annotations were eroded/shrunk by 35 μm to exclude tumours at the edge of the tissue sections.

Tumour core annotations were created by eroding/shrinking vimentin annotations by 10 μm to exclude any small and isolated staining as well as thin processes projecting from the tumour core. The annotation was then dilated/expanded to return the tumour core annotation to its original border size. Any annotations that were smaller than 10,000 μm² were discarded to exclude small islands.

Gross tumour annotations were created by dilating/expanding vimentin annotations by 75 μm to fill in gaps between vimentin staining close together to be considered as part of the gross tumour. These were then eroded/shrunk by 100 μm and then dilated/expanded by 25 μm to smoothen and return to the original border size. Any gross tumour annotations that did not contain a tumour core annotation were discarded.

The tumour’s invasiveness index (II) (Amodeo et al., 2017), independent of tumour size, was calculated as:

\[
\text{Invasiveness index} = \frac{\text{Gross tumour area}}{\text{Tumour core area}}
\]

scRNAseq data analysis
Two public scRNAseq datasets have been analysed: tumour samples from seven newly diagnosed GBM patients (Pombo Antunes et al., 2021, patients ND1-ND7) and from eight GBM patients (Neftel et al., 2019, patients MGH102, MGH105, MGH114, MGH115, MGH118, MGH124, MGH125, MGH126, MGH143), both generated by the 10x Genomics platform. The gene expression matrices were downloaded from https://www.brainimmuneatlas.org/, and GEO (accession number
The gene expression matrices were merged, data was normalised, highly variable genes were detected, and their expression was scaled, followed by PCA, using the Seurat R package (Version 3.2.3). To account for the batch effect between samples, the cellular PCA embedding values were corrected with the harmony R package (Version 1.0), using a diversity clustering penalty parameter (theta) of one. Theta controls the level of alignment between batches, with higher values resulting in stronger correction. Next, the first 20 harmony corrected PCA embeddings were included in Louvain clustering (resolution = 0.25) and UMAP dimensionality reduction, using Seurat. The identified clusters were annotated as myeloid cells, lymphocytes, endothelial cells, and oligodendrocytes, based on expression of cell type markers. The remaining group of clusters were annotated as cancer cells.

The lymphocyte cluster was disaggregated and re-clustered, using 10 harmony corrected PCA embeddings and resolution = 1. By using specific gene markers, the clusters were classified into B cells, regulatory T cells, proliferating CD8 T cells, NKT cells, naive T cells, interferon-response T cells, two clusters of CD4 T cells, two clusters of CD8 T cells, and two clusters of NK cells.

The myeloid cells were also disaggregated and re-clustered based on 30 harmony corrected PCA embeddings, and resolution = 1. We identified monocyte cluster, DC cluster, three clusters of microglia-derived TAMs (mg-TAMs), SEPP1-hi monocyte-derived TAMs (moTAMs), hypoxic moTAMs, IFN-response moTAMs, proliferating moTAMs, TAMs up-regulating heat shock protein genes (HSP TAM: HSPA1A, HSPA1B, HSP90AA1, HSPH1, HSPB1), one cluster specific for patient MGH105, as well as myeloid-cancer cell doublets.

The cancer cells were disaggregated and re-clustered using 20 harmony corrected PCA embeddings, and resolution = 1. One of the clusters, which was expressing macrophage markers, was removed from further analysis as a cluster of macrophage-cancer cell doublets. Additive module scores for the astrocytic (ACS) and OPC gene signatures defined in this study were calculated for each cancer cell, using the AddModuleScore function of Seurat. This function yields the average expression level of each gene signature, subtracted by the average expression of a control gene set. Then, each cell has been assigned the signature with the highest score (ACS, OPC Enrich-300, or OPC Spec-300). Alternatively, additive module scores were calculated for the six gene signatures described by Neftel et al., 2019 (‘MES1’, ‘MES2’, ‘AC’, ‘OPC’, ‘NPC1’, and ‘NPC2’). The six gene signatures were defined using the genes in Supplementary Table S2 of Neftel et al., 2019. Each cell was also assigned the signature with the highest from the six scores. For the gene set enrichment pseudo-bulk analysis of the cancer cells, the raw UMI counts were summed for all cancer cells per gene for each patient using the aggregateAcrossCells function from the scuttle R package (Version 1.0.4). The pseudo-bulk counts were normalised using the CPM method and log2-transformation by edgeR (Version 3.32.1). Gene set ssGSEA enrichment scores for the ACS and OPC signatures, as well as for the six gene signatures of Neftel et al., 2019, were calculated using the GSVAR package (Version 1.38.2).

Spearman’s correlation coefficients have been calculated between ACS pseudo-bulk enrichment score divided by the mean between the two OPC scores per patient, and the percentages of the different cell populations per patient. Furthermore, Spearman’s correlation analysis was performed between the percentages of cells assigned to the distinct gene signatures per patient and the percentages of the different cell subsets present per patient. The data from patients ND7 and MGH143 was not used in these analyses, as they only contain CD45+ and CD45- sorted cells, respectively.

Statistical analysis and graphs
All statistical analysis and generation of graphs was performed using GraphPad Prism 9 or R with appropriate R packages already mentioned. Parametric data are presented as mean ± standard deviation. p<0.05 was considered statistically significant, with p-values <0.0332, <0.0021, <0.0002, <0.0001 represented with *, **, ***, ****, respectively. Further information of the statistical analysis of specific datasets is indicated in the figure legends.

All scatter plots, time-series plots, bar graphs and survival curves, and accompanying statistical tests were generated with GraphPad Prism 9 or R. Venn diagrams were produced using the R package VennDiagram (Chen and Boutros, 2011), for the comparison and visualisation of gene lists. Fisher’s exact tests, used to test the significance of the overlap between Venn diagram categories, were calculated using an online statistics tool (https://www.socscistatistics.com/tests/fisher/default2.aspx) (no reference available). Upset plots showing the number of DEGs found in various patient comparisons
and the overlaps between patient comparisons were generated using the online tool Intervene Shiny App (https://asntech.shinyapps.io/intervene/) (no reference available).

Acknowledgements

This work is funded by grants from Brain Tumour Research (Centre of Excellence award to SM), Cancer Research UK (C23985/A29199 programme award to SM), Barts Charity (MGU0447 programme grant to SM). Part of the study was funded by the National Institute for Health Research to UCLH Biomedical research centre (BRC399/NS/RB/101410 to SB). SB is also supported by the Department of Health’s NIHR Biomedical Research Centre’s funding scheme. We acknowledge the use of data generated by the TCGA Research Network: https://www.cancer.gov/tcga.

Additional information

Funding

| Funder | Grant reference number | Author |
|--------|------------------------|--------|
| Brain Tumour Research Centre of Excellence QMUL | CoE QMUL | James Boot, Gabriel Rosser, Claire Vinel, Nicola Pomella, Loredana Guglielmi, Silvia Marino |
| Cancer Research UK | C23985/A29199 | Xinyu Zhang, Silvia Marino |
| Barts Charity | MGU0447 | Silvia Marino |
| National Institute for Health Research UCLH BRC | (BRC399/NS/RB/101410) | Yau Mun Lim, Sebastian Brandner |

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Author contributions

James Boot, Conceptualization, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing; Gabriel Rosser, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology; Dailya Kancheva, Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology, Writing – review and editing; Claire Vinel, Resources, Formal analysis, Investigation; Yau Mun Lim, Formal analysis, Investigation, Methodology; Nicola Pomella, Formal analysis, Investigation, Visualization; Xinyu Zhang, Formal analysis, Investigation; Loredana Guglielmi, Resources, Supervision; Denise Sheer, Supervision, Writing – review and editing; Michael Barnes, Conceptualization, Supervision; Sebastian Brandner, Resources, Supervision, Visualization, Methodology; Sven Nelander, Kiavash Movahedi, Resources, Supervision, Methodology; Silvia Marino, Conceptualization, Supervision, Funding acquisition, Writing – original draft, Project administration, Writing – review and editing

Author ORCIDs

James Boot http://orcid.org/0000-0002-5629-5026
Yau Mun Lim http://orcid.org/0000-0002-8774-9537
Sven Nelander http://orcid.org/0000-0003-1758-1262
Kiavash Movahedi http://orcid.org/0000-0002-0826-4399
Silvia Marino http://orcid.org/0000-0002-9612-2883

Ethics

All procedures were performed in accordance with licenses held under the UK Animals (Home Office Guidelines: animals Scientific Procedures Act 1986, PPL 70/6452 and P78B6C064Scientific Procedures) Act 1986 and later modifications and conforming to all relevant guidelines and regulations.
Informed consent was obtained and ethical approval was available for the study (National Health Service, Health Research Authority, National Research Ethics Service 08/H0716/16 Amendment 1 17/10/2014).

**Decision letter and Author response**

**Decision letter** https://doi.org/10.7554/eLife.77335.sa1

**Author response** https://doi.org/10.7554/eLife.77335.sa2

**Additional files**

**Supplementary files**

- Supplementary file 1. Differentially expressed genes (DEGs) (log fold change and false discovery ratio [FDR]) from comparisons between patient-matched pairs of glioblastoma initiating cells (GICs) and induced neural stem cells (iNSCs) for 10 patient pairs from this study.
- Supplementary file 2. Differentially expressed genes in the myeloid cell populations of the integrated dataset from newly diagnosed human GBM tumours of Pombo Antunes et al., 2021, and the 10× GBM tumours of Neftel et al., 2019.
- Supplementary file 3. Differentially expressed genes in the lymphocyte cell populations of the integrated dataset from newly diagnosed human GBM tumours of Pombo Antunes et al., 2021, and the 10× GBM tumours of Neftel et al., 2019.
- Supplementary file 4. Media recipes, primer sequences, antibody details, shRNA plasmid details and gene signature lists used in this study.
- Transparent reporting form

**Data availability**

All data generated during this study are included in the manuscript and supporting files, including source files. Sequencing data are available at public repositories.

The following datasets were generated:

| Author(s)        | Year | Dataset title                  | Dataset URL                                      | Database and Identifier               |
|------------------|------|--------------------------------|-------------------------------------------------|---------------------------------------|
| Boot J, Marino S | 2022 | RNASeq data progenitors        | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196418 | NCBI Gene Expression Omnibus, GSE196418 |
| Boot J, Marino S | 2022 | DNA Methyl progenitors         | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE196339  | NCBI Gene Expression Omnibus, GSE196339 |

The following previously published datasets were used:

| Author(s) | Year | Dataset title                                                                 | Dataset URL                                      | Database and Identifier               |
|-----------|------|-------------------------------------------------------------------------------|-------------------------------------------------|---------------------------------------|
| Vinel C, Rosser G, Guglielmi L, Pomella N, Constantinou M, Zhang X, Boot JR, Jones TA, Millner TO, Dumus AA, Rakyvan V, Rees J, Lim YM, Thompson JL, Vuononvirta J, Assan TE, Aley N, Lin Y, Liu P, Sheer D, Merry CL, Marelli-Berg F, Brandner S, Marino S | 2021 | Comparative analysis of glioblastoma initiating cells and patient-matched EPSC-derived neural stem cells as a discovery tool and drug matching strategy [RNA-Seq] | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154958  | NCBI Gene Expression Omnibus, GSE154958 |
Continued

| Author(s)                                      | Year | Dataset title                                                                 | Dataset URL                                                                 | Database and Identifier        |
|------------------------------------------------|------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|-------------------------------|
| Vinel C, Rosser G, Guglielmi L, Pomella N, Constantinou M, Zhang X, Boot JR, Jones TA, Millner TO, Dumas AA, Rakyan V, Rees J, Lim YM, Thompson JL, Vuoronvirta J, Assan TE, Aley N, Lin Y, Liu P, Sheer D, Merry CL, Marelli-Berg F, Brandner S, Marino S | 2021 | Comparative analysis of glioblastoma initiating cells and patient-matched EPSC-derived neural stem cells as a discovery tool and drug matching strategy [array] | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE155985 | NCBI Gene Expression Omnibus, GSE155985 |
| Antunes AR, Scheyltjens I, Lodi F, Messiaen J, Antoran A, Duerinck J, Kancheva D, Martens L, De Vlaminck K, Van Hove H, Hansen SS, Bossio FM, Van der Borght K, De Vleeschouwer S, Sciot R, Bouwens L, Verfaillie M, Vandamme N, Vandenbroucke RE, De Wever O, Saeyes Y, Guilliams M, Gysemans C, Neyns B, De Smet F, Lambrecht D, Van Ginderachter JA, Movahedi K | 2020 | Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE163120 | NCBI Gene Expression Omnibus, GSE163120 |
| De Vlaminck K, Romão E, Puttemans J, Pombo Antunes AR, Kancheva D, Scheyltjens I, Van Ginderachter JA, Myuldermans S, Devoogdt N, Movahedi K, Raes G | 2021 | Single-cell multi-omic profiling of glioblastoma-associated myeloid cells | https://ega-archive.org/studies/EGAS00001004871 | Ega-archive, EGAS00001004871 |
| Nelander S, Johansson P | 2020 | Expression data from “A patient-derived cell atlas of glioblastoma informs precision targeting of the proteasome” (Johansson et al, Cell Reports, 2020) | https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE152160 | NCBI Gene Expression Omnibus, GSE152160 |

References

Alcantara Llaguno SR, Wang Z, Sun D, Chen J, Xu J, Kim E, Hatanpaa KJ, Raisanen JM, Burns DK, Johnson JE, Parada LF. 2015. Adult lineage-restricted CNS progenitors specify distinct glioblastoma subtypes. Cancer Cell 28:429–440. DOI: https://doi.org/10.1016/j.ccell.2015.09.007, PMID: 26461091

Alcantara Llaguno SR, Parada LF. 2016. Cell of origin of glioma: biological and clinical implications. British Journal of Cancer 115:1445–1450. DOI: https://doi.org/10.1038/bjc.2016.354, PMID: 27832665

Alcantara Llaguno S, Sun D, Pedraza AM, Vera E, Wang Z, Burns DK, Parada LF. 2019. Cell-of-origin susceptibility to glioblastoma formation declines with neural lineage restriction. Nature Neuroscience 22:545–555. DOI: https://doi.org/10.1038/s41593-018-0333-8, PMID: 30778149

Amodeo V, Betts J, Bartesaghi S, Zhang Y, Richard-Londt A, Ellis M, Roshani R, Vourí M, Galavotti S, Oberndorfer S, Leite AP, Mackay A, Lampada A, Stratford EW, Li N, Dinsdale D, Grimwade D, Jones C, Nicotera P, Michod D, et al. 2017. A PML/slit axis controls physiological cell migration and cancer invasion in the CNS. Cell Reports 20:411–426. DOI: https://doi.org/10.1016/j.celrep.2017.06.047, PMID: 28700942
et al. 2019. Lncrna MNX1-AS1 promotes glioblastoma progression

Gao Y, Fan X, Li A, Berel D, Madany M, Kim N-H, Liu M, Hymowitz M, Uy B, Jung R, Xu M, Black KL, Edwards LA, Dumas AA, Douvaras P, Fossati V. 2015. Generation and isolation of oligodendrocyte progenitor cells from human

Dobin A, Sun Y, Nadal-Vicens M, Bhatt A, Frank DA, Rozovsky I, Stahl N, Yancopoulos GD, Greenberg ME. 1997. Regulation of gliogenesis in the central nervous system by the JAK-STAT signaling pathway. Science 278:477–483. DOI: https://doi.org/10.1126/science.278.5337.477, PMID: 9343009

Bowman RL, Wang Q, Carro A, Verhaak RGW, Squatrito M. 2017. GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro-Oncology 19:139–141. DOI: https://doi.org/10.1093/neuonc/nox247, PMID: 28031383

Bush NAO, Chang SM, Berger MS. 2017. Current and future strategies for treatment of glioma. Neurosurgical Review 40:1–14. DOI: https://doi.org/10.1007/s10143-016-0705-8, PMID: 27085859

Capper D, Jones DTW, Sill M, Hovestadt V, Schrimpf D, Sturm D, Koelsche C, Sahm F, Chavez L, Reuss DE, Capper D, Chang SM, Berger MS. 2017. Current and future strategies for treatment of glioma. Neurosurgical Reviews 40:1–14. DOI: https://doi.org/10.1007/s10143-016-0705-8, PMID: 27085859

Couturier CP, Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. 2011. Cooperativity with the R/bioconductor package biomart. Bioinformatics 27:341–347. DOI: https://doi.org/10.1093/bioinformatics/btq160, PMID: 21397855

Ceyzériat K, Abjean L, Carrillo-de Sauvage M-A, Ben Haim L, Escartin C. 2016. The complex states of astrocyte reactivity: how are they controlled by the JAK-STAT3 pathway? Neurosciences 330:205–218. DOI: https://doi.org/10.1016/j.neuroscience.2016.05.043, PMID: 27241943

Chen H, Boutros PC. 2011. VennDiagram: a package for the generation of highly-customizable venn and Euler diagrams in R. BMC Bioinformatics 12:35. DOI: https://doi.org/10.1186/1471-2105-12-35, PMID: 21269502

Chow LML, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ. 2011. Cooperativity within and among PTEN, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305–316. DOI: https://doi.org/10.1016/j.ccr.2011.01.039, PMID: 21397855

Couturier CP, Ayyadhury S, Le PU, Nadaf J, Monlong J, Riva G, Allache R, Baig S, Yan X, Bourgey M, Lee C, Wang YCD, Wee Yong V, Guiot M-C, Najafabadi H, Misic B, Antel J, Bourque G, Ragoussis J, Petrecca K. 2020. Single-cell RNA-seq reveals that glioblastoma recapitulates a normal neurodevelopmental hierarchy. Nature Communications 11:3406. DOI: https://doi.org/10.1038/s41467-020-17116-w, PMID: 32641768

Daubon T, Hemadou A, Romero Garmendia I, Saleh M. 2020. Glioblastoma immune landscape and the potential implications of new immunotherapies. Frontiers in Immunology 11:585616. DOI: https://doi.org/10.3389/fimmu.2020.585616, PMID: 33154756

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR. 2013. Star: an ultrafast and memory-efficient RNA-seq aligner. Bioinformatics 29:15–21. DOI: https://doi.org/10.1093/bioinformatics/bts635, PMID: 23104886

Douvaras P, Fossati V. 2015. Generation and isolation of oligodendrocyte progenitor cells from human pluripotent stem cells. Nature Protocols 10:1143–1154. DOI: https://doi.org/10.1038/nprot.2015.075, PMID: 26134954

Dumas AA, Pomella N, Rosser G, Guglielmi L, Vinel C, Millner TO, Rees J, Aley N, Steer D, Wei J, Marisety A, Heimberger AB, Bowman RL, Brandner S, Joyce JA, Marino S. 2020. Microglia promote glioblastoma via mTOR-mediated immunosuppression of the tumour microenvironment. The EMBO Journal 39:e103790. DOI: https://doi.org/10.15252/embj.2019103790, PMID: 32567735

Durinck S, Moreau Y, Kasprzyk A, Davis S, De Moor B, Brazma A, Huber W. 2005. BioMart and bioconductor: a powerful link between biological databases and microarray data analysis. Bioinformatics 21:3439–3440. DOI: https://doi.org/10.1093/bioinformatics/bti525, PMID: 16082012

Durinck S, Spellman PT, Birney E, Huber W. 2009. Mapping identifiers for the integration of genomic datasets with the R/bioconductor package biomaRt. Nature Protocols 4:1184–1191. DOI: https://doi.org/10.1038/nprot.2009.97, PMID: 19617889

Edwards LA, Li A, Berel D, Madany M, Kim N-H, Liu M, Hymowitz M, Uy B, Jung R, Xu M, Black KL, Rentendorj A, Fan X, Zhang W, Xu J, Su Y. 2017. Zeb1 regulates glioma stemness through LIF repression. Scientific Reports 7:531–539. DOI: https://doi.org/10.1038/s41598-017-0700-1, PMID: 28246407

Fan X, Xiong Y, Wang Y. 2019. A reignited debate over the cell (S) of origin for glioblastoma and its clinical implications. Frontiers of Medicine 13:531–539. DOI: https://doi.org/10.1007/s11684-019-0700-1, PMID: 31313083

Gao Y, Xu Y, Wang J, Yang X, Wen L, Feng J. 2019. Lncrna MNX1-AS1 promotes glioblastoma progression through inhibition of miR-4443. Oncology Research 27:341–347. DOI: https://doi.org/10.3727/09650418X15228909735079, PMID: 29678219
induction of glioblastoma cells. Molecular Oncology 13:1589–1604. DOI: https://doi.org/10.1002/1878-0261.12525, PMID: 31162799

Maksimovic J, Gordon L, Oshlack A. 2012. Subset-quantile within array normalization for illumina infinium humanmethylatin450 beadchips. Genome Biology 13.R44. DOI: https://doi.org/10.1186/gb-2012-13-6-r44, PMID: 22703947

Malka TM, Sokolov A, Gentles AJ, Burzyskowski T, Poisson L, Weinstein JN, Kamińska B, Huelsen J, Ombreg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn K, Krasnitz A, Godwin AK, Lazar AJ, Cancer Genome Atlas Research Network, Stuart JM, et al. 2018. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173:338–354. DOI: https://doi.org/10.1016/j.cell.2018.03.034, PMID: 29625051

Marshall CAG, Goldman JE. 2002. Subpallial dlx2-expressing cells give rise to astrocytes and oligodendrocytes in the cerebral cortex and white matter. The Journal of Neuroscience 22:9821–9830. DOI: https://doi.org/10.1523/jneurosci.22-22-09821.2002, PMID: 12427838

Mattern A, Zellmann T, Beck-Sickinge AG. 2014. Processing, signaling, and physiological function of chemerin. IUBMB Life 66:19–26. DOI: https://doi.org/10.1002/iub.24466308

McCarthy DJ, Chen Y, Smyth GK. 2012. Differential expression analysis of multifactor RNA-seq experiments with respect to biological variation. Nucleic Acids Research 40:4288–4297. DOI: https://doi.org/10.1093/nar/gks042, PMID: 22287627

McKenzie AT, Wang M, Hauber MB, Fullard JF, Kozenkov A, Keenan A, Hurd YL, Dracheva S, Casaccia P, Rousso P, Zhang B. 2018. Brain cell type specific gene expression and co-expression network architectures. Scientific Reports 8:8868. DOI: https://doi.org/10.1038/s41598-018-27929-5, PMID: 29892006

Morriss TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarty AR, Wojdacz TK, Beck S. 2014. Champ: 450k CHIP analysis methylation pipeline. Bioinformatics 30:428–430. DOI: https://doi.org/10.1093/bioinformatics/btt684, PMID: 24336642

Nakashima K, Yanagisawa M, Arakawa H, Taga T. 1999. Astrocyte differentiation mediated by LIF in cooperation with BMP2. FEBS Letters 457:43–46. DOI: https://doi.org/10.1016/s0014-5793(99)00997-7, PMID: 10486560

Namihira M, Kohyama J, Sem K, Sanosaka T, Deneen B, Taga T, Nakashima K. 2009. Committed neuronal precursors confer astrocytic potential on residual neural precursor cells. Developmental Cell 16:245–255. DOI: https://doi.org/10.1016/j.devcel.2008.12.014, PMID: 19217426

Nefelt C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, Dewitt J, Gritsch S, Perez EM, Gonzalez Castro LN, Lan X, Druck N, Rodman C, Dionne D, Kaplan A, Bertalan MS, et al. 2019. An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell 178:835–849. DOI: https://doi.org/10.1016/j.cell.2019.06.024, PMID: 31327527

Nowakowski TJ, Bhaduri A, Pollen AA, Alvarado B, Mostajo- Radji MA, Di Lullo E, Haeussler M, Butcher LM, Feber A, Teschendorff AE, Chakravarty AR, Wojdacz TK, Beck S. 2014. Champ: 450k CHIP analysis methylation pipeline. Bioinformatics 30:428–430. DOI: https://doi.org/10.1093/bioinformatics/btt684, PMID: 24336642

Palmer AB, Weick RA, De Vlaminck K, Van Hove H, Kjølner Hansen SS, Bosisio FM, Van der Borght K, De Vleeschouwer S, Sciot R, Griffiths JA, Kornblith AB, Casto AM, de la Maza MY, Santos CC, Deneen B, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8:2281–2308. DOI: https://doi.org/10.1038/nprot.2013.143, PMID: 24157548

Petrovsky N, Ewbank JT, McDonald JH, Cusanovich MA, Dudoit S, Gifford DK. 2013. A master regulatory gene transcription module of glioblastoma reveals a preceding stemness program. Nature Communications 4:1152. DOI: https://doi.org/10.1038/ncomms1152, PMID: 23405830

Peña S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. 2009. Tgf-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15:315–327. DOI: https://doi.org/10.1016/j.ccr.2009.02.011, PMID: 19345330

Peters TJ, Buckley MJ, Statham AL, Pidsley R, Samaras K, V Lord R, Clark SJ, Molloy PL. 2015. De novo identification of differentially methylated regions in the human genome. Epigenetics & Chromatin 8:8. DOI: https://doi.org/10.1186/1756-8935-8-6, PMID: 25972926

Pombo Antunes AR, Sechehtgens I, Lodi F, Messiaen J, Antoranz A, Duerinck J, Kancheva D, Martens L, De Vlamink K, Van Hove H, Kjølner Hansen SS, Bosio FM, Van der Borght K, De Vleeschouwer S, Sciorti R, Bouwens L, Verfaillie M, Vandamme N, Vandenbroucke RE, De Wever O, et al. 2021. Single-Cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nature Neuroscience 24:595–610. DOI: https://doi.org/10.1038/s41593-020-00789-y, PMID: 33782623

Puchalski RB, Shah N, Miller J, Dalley R, Nomura SR, Yoon J-G, Smith KA, Lankerovich M, Bertagnolli D, Bickley K, Boe AF, Brouner K, Butler S, Caldejon S, Chapin M, Datta S, Dee N, Desta T, Bolleare T, Dotson N, et al. 2018. An anatomic transcriptional atlas of human glioblastoma. Science 360:660–663. DOI: https://doi.org/10.1126/science.aaf2666, PMID: 29748285

Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. Nature Protocols 8:2281–2308. DOI: https://doi.org/10.1038/nprot.2013.143, PMID: 24157548

Robinson MD, McCarthy DJ, Smyth GK. 2010. EdgeR: a bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26:139–140. DOI: https://doi.org/10.1093/bioinformatics/btp616, PMID: 19910308

Boot et al. eLife 2022;11:e77335. DOI: https://doi.org/10.7554/eLife.77335
Rose NR, Klose RJ. 2014. Understanding the relationship between DNA methylation and histone lysine methylation. Biochimica et Biophysica Acta 1839:1362–1372. DOI: https://doi.org/10.1016/j.bbagen.2014.02.007, PMID: 24560929

Saghaftinia S, Mina M, Riggi N, Hanahan D, Ciriello G. 2018. Pan-Cancer landscape of aberrant DNA methylation across human tumors. Cell Reports 25:1066–1080. DOI: https://doi.org/10.1016/j.celrep.2018.09.082, PMID: 30355485

Sanesaka T, Imamura T, Hamazaki N, Chai M, Igarashi K, Ideta-Otsuka M, Miura F, Ito T, Fujii N, Ikeo K, Nakashima K. 2017. Dna methylase analysis identifies transcription factor-based epigenomic signatures of multilineage competence in neural stem/progenitor cells. Cell Reports 20:2992–3003. DOI: https://doi.org/10.1016/j.celrep.2017.08.086, PMID: 28930691

Schwieck J, Eickholt BJ, Murk K. 2018. Important shapeshifter: mechanisms allowing astrocytes to respond to the changing nervous system during development, injury and disease. Frontiers in Cellular Neuroscience 12:261. DOI: https://doi.org/10.3389/fncel.2018.00261, PMID: 30186118

Schmidt-Edelkraut U, Hoffmann A, Daniel G, Spengler D. 2013. Zac1 regulates astroglial differentiation of neural stem cells through SOCS3. Stem Cells 31:1621–1632. DOI: https://doi.org/10.1002/stem.1405, PMID: 23630160

Sehn T, Sachse C, Frenzel C, Echeverri K. 2009. MiR-196 is an essential early-stage regulator of tail regeneration, upstream of key spinal cord patterning events. Developmental Biology 334:468–480. DOI: https://doi.org/10.1016/j.ydbio.2009.08.008, PMID: 19682983

Sturm D. 2012. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437. DOI: https://doi.org/10.1016/j.cccr.2012.08.024, PMID: 23079654

Tahiliani M, Koh KP, Shen Y, Pastor WA, Bandukwala H, Brudno Y, Agarwal S, Iyer LM, Liu DR, Aravind L, Rao A. 2009. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930–935. DOI: https://doi.org/10.1126/science.1170116, PMID: 19372391

Tanaka K, Arao T, Maegawa M, Matsumoto K, Kudo K, Fujita Y, Yokote H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K. 2009. Srpx2 is overexpressed in gastric cancer and promotes cellular migration and adhesion. International Journal of Cancer 124:1072–1080. DOI: https://doi.org/10.1002/ijc.24065, PMID: 19065654

Tang H, Zhao J, Zhang L, Zhao J, Zhuang Y, Liang P. 2016. Srpx2 enhances the epithelial-mesenchymal transition and temozolomide resistance in glioblastoma cells. Cellular and Molecular Neurobiology 36:1067–1076. DOI: https://doi.org/10.1007/s10571-015-0300-9, PMID: 26643178

Tarazona S, García-Alcalde F, Dopazo J, Ferrer A, Conesa A. 2011. Differential expression in RNA-Seq: a matter of depth. Genome Research 21:2213–2223. DOI: https://doi.org/10.1101/gr.124321.111, PMID: 21903743

Tew J, Wang M, Pimenova AA, Bowles KR, Hartley BJ, Lacin E, Machlovi SI, Abdelaii R, Karch CM, Phatnani H, Tiwari N, Morris TJ, Webster AP, Yang Z, Beck S, Feber A, Teschendorff AE. 2017. Champ: updated methylation analysis pipeline for illumina beadchips. Bioinformatics 33:3982–3984. DOI: https://doi.org/10.1093/bioinformatics/btx513, PMID: 28961746

Tiwari VK, Berninger B. 2018. Stage-specific transcription factors drive astrogliogenesis by remodeling gene regulatory landscapes. Stem Cell Reports 23:557–571. DOI: https://doi.org/10.1016/j.stemcr.2018.09.008, PMID: 30290178

Treek O, Buechler C, Oertmann O. 2019. Chemerin and cancer. International Journal of Molecular Sciences 20:E3750. DOI: https://doi.org/10.3390/ijms20153750, PMID: 31370263

Vinel C, Rosser G, Guglielmi L, Constantinou M, Pomella N, Zhang X, Boot JR, Jones TA, Millner TO, Dumas AA, Rakyan V, Rees J, Thompson JL, Vuononvirta J, Nadkarni S, El Assan T, Aley N, Lin Y-Y, Liu P, Nelander S, et al. 2021. Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. Nature Communications 12:6130. DOI: https://doi.org/10.1038/s41467-021-26297-6, PMID: 34675201

Vivinnetto AL, Kim ID, Goldberg DC, Fones L, Brown E, Tarabyskin VS, Hill CE, Cho S, Cave JW. 2020. Zeb2 is a regulator of astrogliosis and functional recovery after CNS injury. Cell Reports 31:107834. DOI: https://doi.org/10.1016/j.celrep.2020.107834, PMID: 32610135

Wang Q, Hu H, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Sauvé CEG, Olar A, Lan ZD, et al. 2017a. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell 32:42–56. DOI: https://doi.org/10.1016/j.ccell.2017.06.003, PMID: 28697342

Wang T, Liu X, Tian Q, Liang T, Chang P. 2017b. Increasing expression of mir-5100 in non-small-cell lung cancer and correlation with prognosis. European Review for Medical and Pharmacological Sciences 21:3592–3597, PMID: 28925485.

Wen PY, Kesari S. 2008. Malignant gliomas in adults. The New England Journal of Medicine 359:492–507. DOI: https://doi.org/10.1056/NEJMra0708126, PMID: 18669428
Wenger A, Ferreyra Vega S, Kling T, Bontell TO, Jakola AS, Carén H. 2019. Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification. *Neuro-Oncology* **21:**616–627. DOI: https://doi.org/10.1093/neuonc/noz011, PMID: 30668814

Wickham H. 2009. Elegant graphics for data analysis. 3.1.1. Ggplot2.

Wilkinson AC, Ryan DJ, Kucinski I, Wang W, Yang J, Nestorowa S, Diamanti E, Tsang JC-H, Wang J, Campos LS, Yang F, Fu B, Wilson N, Liu P, Gottgens B. 2019. Expanded potential stem cell media as a tool to study human developmental hematopoiesis in vitro. *Experimental Hematology* **76:**1–12.. DOI: https://doi.org/10.1016/j.exphem.2019.07.003, PMID: 31326613

Xiao Q, Du Y, Wu W, Yp HK. 2010. Bone morphogenetic proteins mediate cellular response and, together with noggin, regulate astrocyte differentiation after spinal cord injury. *Experimental Neurology* **221:**353–366. DOI: https://doi.org/10.1016/j.expneurol.2009.12.003, PMID: 2005873

Xie Y, Bergström T, Jiang Y, Johansson P, Marinescu VD, Lindberg N, Segerman A, Wicher G, Niklasson M, Baskaran S, Sreedharan S, Everlien I, Kastemar M, Hermansson A, Elfineh L, Libard S, Holland EC, Hesselager G, Alafuzoff I, Westermark B, et al. 2015. The human glioblastoma cell culture resource: validated cell models representing all molecular subtypes. *EBioMedicine* **2:**1351–1363. DOI: https://doi.org/10.1016/j.ebiom.2015.08.026, PMID: 26629530

Yang H, Wang Y. 2016. Five miRNAs considered as molecular targets for predicting neuroglioma. *Tumour Biology* **37:**1051–1059. DOI: https://doi.org/10.1007/s13277-015-3898-9, PMID: 26269115

Yang J, Ryan DJ, Wang W, Tsang JC-H, Lan G, Masaki H, Gao X, Antunes L, Yu Y, Zhu Z, Wang J, Kolodziejczyk AA, Campos LS, Wang C, Yang F, Zhong Z, Fu B, Eckersley-Maslin MA, Woods M, Tanaka Y, et al. 2017. Establishment of mouse expanded potential stem cells. *Nature* **550:**393–397. DOI: https://doi.org/10.1038/nature24052, PMID: 29019987

Yin KJ, Hamblin M, Fan Y, Zhang J, Chen YE. 2015. Krüpple-Like factors in the central nervous system: novel mediators in stroke. *Metabolic Brain Disease* **30:**401–410. DOI: https://doi.org/10.1007/s11011-013-9468-1, PMID: 24338065

Zhang M, Li X, Fan Z, Zhao J, Liu S, Zhang M, Li H, Goscinis MA, Fan H, Suo Z. 2018. High SRPX2 protein expression predicts unfavorable clinical outcome in patients with prostate cancer. *OncoTargets and Therapy* **11:**3149–3157. DOI: https://doi.org/10.2147/OTT.S158820, PMID: 29881288

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen A-J, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA. 2008. P53 and PTEN control neural and glioma stem/progenitor cell renewal and differentiation. *Nature* **455:**1129–1133. DOI: https://doi.org/10.1038/nature07443, PMID: 18948956

Ziv-Av A, Giladi ND, Lee HK, Cazacu S, Finniss S, Xiang C, Pauler MH, Barba-Saad M, Poisson L, Brodie C. 2015. Rtvp-1 regulates glioma cell migration and invasion via interaction with N-WASP and hnRNP K. *OncoTarget* **6:**19826–19840. DOI: https://doi.org/10.18632/oncotarget.4471, PMID: 26305187